<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nanomaterials (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Nanomaterials (Basel)</journal-id><journal-id journal-id-type="publisher-id">nanomaterials</journal-id><journal-title-group><journal-title>Nanomaterials</journal-title></journal-title-group><issn pub-type="epub">2079-4991</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7352498</article-id><article-id pub-id-type="doi">10.3390/nano10061072</article-id><article-id pub-id-type="publisher-id">nanomaterials-10-01072</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4539-3544</contrib-id><name><surname>Nasrollahzadeh</surname><given-names>Mahmoud</given-names></name><xref ref-type="aff" rid="af1-nanomaterials-10-01072">1</xref><xref rid="c1-nanomaterials-10-01072" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Sajjadi</surname><given-names>Mohaddeseh</given-names></name><xref ref-type="aff" rid="af1-nanomaterials-10-01072">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0441-7247</contrib-id><name><surname>Soufi</surname><given-names>Ghazaleh Jamalipour</given-names></name><xref ref-type="aff" rid="af2-nanomaterials-10-01072">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3985-7928</contrib-id><name><surname>Iravani</surname><given-names>Siavash</given-names></name><xref ref-type="aff" rid="af3-nanomaterials-10-01072">3</xref><xref rid="c1-nanomaterials-10-01072" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9731-6228</contrib-id><name><surname>Varma</surname><given-names>Rajender S.</given-names></name><xref ref-type="aff" rid="af4-nanomaterials-10-01072">4</xref><xref rid="c1-nanomaterials-10-01072" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-nanomaterials-10-01072"><label>1</label>Department of Chemistry, Faculty of Science, University of Qom, Qom 37185-359, Iran; <email>mhd.sajjadi@gmail.com</email></aff><aff id="af2-nanomaterials-10-01072"><label>2</label>Radiology Department, School of Medicine, Isfahan University of Medical Sciences, Isfahan 81746 73461, Iran; <email>Jamalipour@med.mui.ac.ir</email></aff><aff id="af3-nanomaterials-10-01072"><label>3</label>Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan 81746 73461, Iran</aff><aff id="af4-nanomaterials-10-01072"><label>4</label>Regional Centre of Advanced Technologies and Materials, Palack&#x000fd; University in Olomouc, &#x00160;lechtitel&#x0016f; 27, 783 71, CZ-779 00 Olomouc, Czech Republic</aff><author-notes><corresp id="c1-nanomaterials-10-01072"><label>*</label>Correspondence: <email>mahmoudnasr81@gmail.com</email> (M.N.); <email>siavashira@gmail.com</email> (S.I.); <email>Varma.Rajender@epa.gov</email> (R.S.V.)</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2020</year></pub-date><volume>10</volume><issue>6</issue><elocation-id>1072</elocation-id><history><date date-type="received"><day>01</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>20</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Viral infections have recently emerged not only as a health threat to people but rapidly became the cause of universal fatality on a large scale. Nanomaterials comprising functionalized nanoparticles (NPs) and quantum dots and nanotechnology-associated innovative detection methods, vaccine design, and nanodrug production have shown immense promise for interfacing with pathogenic viruses and restricting their entrance into cells. These viruses have been scrutinized using rapid diagnostic detection and therapeutic interventional options against the caused infections including vaccine development for prevention and control. Coronaviruses, namely SARS-CoV, MERS-CoV, and SARS-CoV-2, have endangered human life, and the COVID-19 (caused by SARS-CoV-2) outbreak has become a perilous challenge to public health globally with huge accompanying morbidity rates. Thus, it is imperative to expedite the drug and vaccine development efforts that would help mitigate this pandemic. In this regard, smart and innovative nano-based technologies and approaches encompassing applications of green nanomedicine, bio-inspired methods, multifunctional bioengineered nanomaterials, and biomimetic drug delivery systems/carriers can help resolve the critical issues regarding detection, prevention, and treatment of viral infections. This perspective review expounds recent nanoscience advancements for the detection and treatment of viral infections with focus on coronaviruses and encompasses nano-based formulations and delivery platforms, nanovaccines, and promising methods for clinical diagnosis, especially regarding SARS-CoV-2.</p></abstract><kwd-group><kwd>nanotechnology</kwd><kwd>nanoparticles</kwd><kwd>quantum dots</kwd><kwd>graphene oxide</kwd><kwd>nanovaccines</kwd><kwd>coronaviruses</kwd><kwd>COVID-19</kwd><kwd>viral infections</kwd><kwd>SARS-CoV-2</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-nanomaterials-10-01072"><title>1. Introduction</title><p>Presently, the outbreak of viral respiratory infections is rampant and spreading all over the world, and researchers are urgently aiming to identify and develop suitable nanovaccines and therapeutic options including emerging nano-based options. Viruses are a small obligate intracellular parasite and are non-living outside a host cell, whose interactions with them mostly include receptor-ligand interactions; respiratory viruses, among them, represent serious threats for all demographics. Importantly, the need for drug design and discovery is prompted by inherent characteristics of viral illnesses that contain complexities in lifecycle stages, main alterations in replication dynamics, diverse stages of replication in assorted subcellular organelles or compartments, development of drug resistance, and the feasibility of latent viral infections in an inaccessible biological compartment, among others. The quick advancement of drug resistance to recently accessible treatments and the adverse health impacts owing to their protracted use has become a critical health issue. Over the last 20&#x02009;years, few old illnesses have re-emerged, and many new infectious disease agents, especially viruses, have appeared, with human immunodeficiency virus (HIV) and acute respiratory infections being the leading causes of death worldwide [<xref rid="B1-nanomaterials-10-01072" ref-type="bibr">1</xref>,<xref rid="B2-nanomaterials-10-01072" ref-type="bibr">2</xref>,<xref rid="B3-nanomaterials-10-01072" ref-type="bibr">3</xref>,<xref rid="B4-nanomaterials-10-01072" ref-type="bibr">4</xref>]. Owing to emergence of a diversity of novel variants of pathogenic viruses, the lack of immunization and therapy of infectious illnesses have become a critical challenge and a clinical threat in an exceedingly short span of time.</p><p>The human respiratory mucosa is the most significant portal and the primary site of entry for incursion or infection by various viruses such as the influenza virus, the respiratory syncytial virus, and the parainfluenza virus, among others. These virulent pathogens initially infect the upper respiratory tract and then reach the lower breathing airways (or lower respiratory tract), leading to death. Lower respiratory tract illnesses explicate a leading cause of human morbidity and mortality with ~3 million deaths annually worldwide [<xref rid="B5-nanomaterials-10-01072" ref-type="bibr">5</xref>]. These pathogens often enter the host via airborne transmissions (animal/human-to-human) and then spread through direct contact or droplets/aerosols, effectively replicate in the respiratory tract, and mostly cause clinical symptoms/manifestations, namely fever, dyspnea, cough, bronchiolitis, and/or pneumonia [<xref rid="B6-nanomaterials-10-01072" ref-type="bibr">6</xref>]. Most respiratory tract infections are due to one of the numerous respiratory viruses, mostly influenza virus, respiratory syncytial virus (RSV), rhinovirus (RV), and severe/acute respiratory syndrome (SARS), infecting the person&#x02019;s lower respiratory tract [<xref rid="B7-nanomaterials-10-01072" ref-type="bibr">7</xref>,<xref rid="B8-nanomaterials-10-01072" ref-type="bibr">8</xref>,<xref rid="B9-nanomaterials-10-01072" ref-type="bibr">9</xref>,<xref rid="B10-nanomaterials-10-01072" ref-type="bibr">10</xref>]. Nevertheless, adenovirus, parainfluenza virus, enterovirus, and human bocavirus (HBoV) and human metapneumovirus (HMPV) can also play relevant roles, especially during epidemics [<xref rid="B11-nanomaterials-10-01072" ref-type="bibr">11</xref>]. Most of these infections (~80%) are caused by the viruses summarized in <xref ref-type="fig" rid="nanomaterials-10-01072-f001">Figure 1</xref> and <xref ref-type="fig" rid="nanomaterials-10-01072-f002">Figure 2</xref> [<xref rid="B9-nanomaterials-10-01072" ref-type="bibr">9</xref>].</p><p>Respiratory viruses generally present a main health issue in infants, children, elderly people, and/or immunocompromised patients. Parainfluenza virus [<xref rid="B13-nanomaterials-10-01072" ref-type="bibr">13</xref>] and/or RSV [<xref rid="B14-nanomaterials-10-01072" ref-type="bibr">14</xref>] infections are the leading causes of hospitalization for acute respiratory illnesses in children, leading to 40% and 45% of pediatric hospitalizations, respectively. Among these viral infections, 3~5% of the lower respiratory tract illness cases in children are caused by adenovirus infections [<xref rid="B15-nanomaterials-10-01072" ref-type="bibr">15</xref>]. SARS, the most recent infectious illness, is generally an acute form of bronchopneumonia, which could be caused by a novel coronavirus (CoV). Astoundingly, CoVs are the main pathogens that primarily target the human respiratory system. The first emergence of &#x0201c;SARS-CoV&#x0201d; infections (8-month outbreak) had a fatality rate of ~10%, which resulted in over 8000 confirmed cases [<xref rid="B10-nanomaterials-10-01072" ref-type="bibr">10</xref>]. In 2012, after ten years, the Middle East respiratory syndrome &#x0201c;(MERS)-CoV&#x0201d; emerged in a universal outbreak, which was transmitted to almost 27 countries (<uri xlink:href="https://www.who.int/emergencies/mers-cov/en/">https://www.who.int/emergencies/mers-cov/en/</uri>; 2013). At the end of 2019, 2019-nCoV (emerging novel CoV), as a potentially deadly &#x0201c;SARS-CoV-2&#x0201d; (severe/acute respiratory syndrome CoV 2) presented a critical threat and a global concern to vulnerable populations within an extremely short time span [<xref rid="B16-nanomaterials-10-01072" ref-type="bibr">16</xref>]. Astoundingly, these emerging SARS-CoVs are more likely to ensue in the elderly population, particularly those who suffer from hypertension, diabetes, and cardiovascular or coronary heart illness. At least half of these patients are tremendously susceptible to infection, which may turn into a cytokine storm, septic shock, metabolic acidosis coagulation dysfunction, acute respiratory distress syndrome (ARDS), heading to demise. We are today witnessing a global transmission of SARS-CoV-2 with more than 4,178,156 positive cases and at least over 286,353 deaths, transmitted from China to over 212 countries/regions. Now, various antiviral agents and proposed drugs are under clinical trial evaluations for their potential effects against SARS-CoV-2, but they are in the initial stages, and crucial issues, including pharmacokinetic characteristics, drugs availability, and potential side effects, should be analyzed astutely [<xref rid="B17-nanomaterials-10-01072" ref-type="bibr">17</xref>].</p><p>Efficient treatments against viruses are hindered by the advancement of drug resistance and non-specific targeting, particularly those associated with influenza [<xref rid="B18-nanomaterials-10-01072" ref-type="bibr">18</xref>] and HIV [<xref rid="B19-nanomaterials-10-01072" ref-type="bibr">19</xref>,<xref rid="B20-nanomaterials-10-01072" ref-type="bibr">20</xref>]. Indeed, the main challenges to combat such epidemic viral infections are that for several of them (especially SARS-CoV infections) there are no effective antiviral drugs or specific treatments accessible, thus designing potent drugs to combat these diseases needs to be pursued urgently. Collectively, control or prevention of the pathogenicity of viruses is probably the best and possibly only way to diminish public health challenges resulting from viral illnesses. Efforts to control these respiratory infections are focused on prevention via vaccine advancement.</p><p>This perspective begins with a broader overview of newer strategies in vaccine design with illustration of the nano-based formulation approaches against viruses that are being developed as delivery vehicles, including novel nanovaccine transfer platforms and useful nanodrugs for treatment of viral infection.</p></sec><sec id="sec2-nanomaterials-10-01072"><title>2. Nanotechnology against Viral Infections with Focus on CoVs</title><p>Nanotechnology and nanoscience refers to the improvement, advancement or application of atomic/molecular structures with at least one dimension that is in the nanoscale range (1~100 nm) with variable composition, shape/morphology, size, or surface properties [<xref rid="B21-nanomaterials-10-01072" ref-type="bibr">21</xref>,<xref rid="B22-nanomaterials-10-01072" ref-type="bibr">22</xref>,<xref rid="B23-nanomaterials-10-01072" ref-type="bibr">23</xref>,<xref rid="B24-nanomaterials-10-01072" ref-type="bibr">24</xref>]. Over the decades, NPs/nanocarriers have been utilized in a diversity of new pharmaceutical applications, namely effective delivery of drugs to the targeted sites without exposing the healthy tissue cells, sensitive imaging to detect viral illnesses at early stages, and crossing these barriers (e.g., the epithelial/endothelial, immunological, or cellular barriers) to deliver nano-therapeutic molecules or nanovaccines to specific diseased organs or cell tissues as well as to interact with biomolecules in the blood or within organ tissues. Additionally, the inactivation of viruses by using engineered nanomaterials (acid functionalized multi-walled carbon nanotube comprising photo-activated molecules) and inhibition of viral binding with the host cell surface receptor are important examples of nano-based approaches against viruses (e.g., angiotensin-converting enzyme 2 (ACE2) receptor, especially in the case of SARS-CoV-2) (<xref ref-type="fig" rid="nanomaterials-10-01072-f003">Figure 3</xref>). Besides their nanoscale size, nanocarriers can efficiently deliver antigens owing to ease of surface functionalization and have capability to co-transport antigens accompanied by numerous adjuvants. One of the significant requirements for any efficient (nano)medicinal agent is the delivery to the proper place at the appropriate concentrations within a suitable time period [<xref rid="B25-nanomaterials-10-01072" ref-type="bibr">25</xref>].</p><p>Two kinds of passive or active targeting mechanisms are commonly possible. In a targeted nanoparticulate delivery system, passive targeting could occur because of the enhanced permeability or leakiness (causing by inflammation or malignancy) of a local vasculature, which can result in the sick section growing more accommodating to the buildup of nanotherapeutic agent. Instead, active targeting is associated with attachment of targeting ligands (e.g., antibodies, carbohydrates, peptides, proteins, etc.) to direct the nanotherapeutic entity to a specific receptor, site, or epitope. Incorporation of the nuclear localization signals on the nanocarrier in active targeted nanoparticulate delivery systems is thus desirable to enhance specificity. Active targeting is thus a significant requirement for the remediation of virus infections since numerous antiviral nanodrugs are essential to ensure they are confined at particular subcellular organelles/regions, depending on the replication stages and the (nano)drug&#x02019;s modes of action. Along this line, integrase inhibitors effectively prevent the strand transfer reaction of the virus lifecycle stages (e.g., HIV integrase, which is responsible for the attachment of viral DNA into host/cell chromosomes) [<xref rid="B26-nanomaterials-10-01072" ref-type="bibr">26</xref>].</p><p>Other unmet enquiries in viral management options comprise the utilization of RNA-mediated interference technology, which is a promising molecular tactic for the handling of a variety of infectious illnesses [<xref rid="B27-nanomaterials-10-01072" ref-type="bibr">27</xref>]. Indeed, there are limitations that prohibit validity and clinical utility of small/short interfering RNA (siRNA) therapeutics, including the inability of RNA to traverse the membrane of a cell (owing to the big molecular weight and/or negative charge), as well as expeditious renal sanction, uptake, or poisonousness (owing to aroused immune reaction) [<xref rid="B27-nanomaterials-10-01072" ref-type="bibr">27</xref>,<xref rid="B28-nanomaterials-10-01072" ref-type="bibr">28</xref>]. To overcome such restrictions, the incorporation of siRNA within or onto the NPs/nanocarriers could attain successful viral replication inhibition; developments of efficient and novel treatment approaches are thus imperative. For instance, silver NPs with antiviral effects were green synthesized using curcumin as a reducing agent; curcumin modified silver NPs had a remarkable inhibitory effect against respiratory syncytial virus (RSV) infection [<xref rid="B29-nanomaterials-10-01072" ref-type="bibr">29</xref>]. Nanotechnology-based platforms for nanotherapeutic drugs that are successfully approved or under further investigation for treating or inhibiting viral infections are summarized in <xref rid="nanomaterials-10-01072-t001" ref-type="table">Table 1</xref>. Additionally, some significant engineered nanomaterials for the diagnosis and inhibition of CoVs are summarized in <xref rid="nanomaterials-10-01072-t002" ref-type="table">Table 2</xref>.</p><p>The present medications for MERS-CoV are engendered from H1N1 flu and SARS-CoV outbursts [<xref rid="B54-nanomaterials-10-01072" ref-type="bibr">54</xref>,<xref rid="B55-nanomaterials-10-01072" ref-type="bibr">55</xref>,<xref rid="B56-nanomaterials-10-01072" ref-type="bibr">56</xref>,<xref rid="B57-nanomaterials-10-01072" ref-type="bibr">57</xref>]. These incorporate various mixes of little particles with expansive antiviral action (e.g., corticosteroids, interferons, and ribavirin) and polyclonal/monoclonal antibodies for therapeutic options [<xref rid="B56-nanomaterials-10-01072" ref-type="bibr">56</xref>,<xref rid="B58-nanomaterials-10-01072" ref-type="bibr">58</xref>]. Membrane-anchored glycoprotein S has of late been seen as a basis for the connection between the host cell and MERS-CoV [<xref rid="B58-nanomaterials-10-01072" ref-type="bibr">58</xref>,<xref rid="B59-nanomaterials-10-01072" ref-type="bibr">59</xref>], and the improvement of MERS-CoV entrance inhibitors focusing on the S1 subunit can be deemed as a suitable antiviral practice. As of late, nanomaterials have attained favorable stature to alter the cycle of viral infection [<xref rid="B60-nanomaterials-10-01072" ref-type="bibr">60</xref>]. The virus entrance into the host cells might be supported by multivalent connections. The similar trait of nanostructured materials possessing high surface to volume proportion and permitting the addition of ligands on their surfaces may thus meddle with viral connection and block its entrance into cells [<xref rid="B57-nanomaterials-10-01072" ref-type="bibr">57</xref>].</p><p>In one investigation, heptad repeat 1 (HR1) peptide inhibitors were examined for inhibiting HR1/HR2-mediated sheath merging among MERS-CoV and host cells, the main conduit for host infections induced by MERS-CoV [<xref rid="B61-nanomaterials-10-01072" ref-type="bibr">61</xref>]. Mainly, the inhibitory influences of peptide pregnancy-prompted hypertension have been accelerated 10-fold by generation of a gold nanorod complex. Additionally, this complex showed improved biocompatibility and metabolic strength, both in vivo and in vitro, thus successfully forestalling sheath merging prompted by MERS-CoV [<xref rid="B61-nanomaterials-10-01072" ref-type="bibr">61</xref>].</p><p>Additionally, triangular star-shaped bovine serum albumin (BSA)-coated tellurium NPs reportedly suppressed virus infection predominantly by obstructing the virus internalization procedure; these nanostars showed remarkable antiviral activities against porcine epidemic diarrhea virus (PEDV) (e.g., CoV) [<xref rid="B62-nanomaterials-10-01072" ref-type="bibr">62</xref>].</p><sec id="sec2dot1-nanomaterials-10-01072"><title>2.1. Nano-Based Advances for Viral Detection</title><p>With the evident possibility of enormous outbreaks, the situation is very quickly growing more critical, and the need for the development of quick diagnostics and effective control strategies is becoming graver. The diagnostic field was boosted early in the 1980s with two main advancements, namely the birth of diverse immunoassays and the invention of polymerase chain reaction (PCR). The first study on the serological detection technique of viruses with different immunoassays was described in 1970, in which a radioimmunoassay was utilized towards the detection of the Australia antigen, which was later labeled, the HBs Ag (hepatitis B surface antigen) [<xref rid="B63-nanomaterials-10-01072" ref-type="bibr">63</xref>]. In the mid-20th century, electron microscopy and cell/tissue culture techniques were discovered that are still usually employed for the direct detection of diverse viruses [<xref rid="B64-nanomaterials-10-01072" ref-type="bibr">64</xref>] and subsequently led to an array of serological and molecular detection techniques. Molecular techniques are comparatively more sensitive and are quicker than immunoassays and could be utilized not only in a facile form towards the manual detection of a virus but also as the embedded component of more complex systems. Despite these promising applications, most molecular means still have diverse potential limitations in accuracy, repeatability, specificity, and sensitivity, often caused by the high genetic variability of several viruses. In addition, the traditional techniques for respiratory virus detection are generally costly, time consuming, labor intensive, and require specialized laboratory equipment and expertise.</p><p>Nanotechnologies are presently focused on pathogenic viruses and are geared up for detection of viral infections. In this respect, gold (Au) NPs and quantum dots (QDs) have become key components in the improvement/advancement of novel nanotechnology-based detection for several respiratory viruses; Au NPs have been combined with silver staining and utilized for the detection of HPV (human papillomavirus) in a cervical carcinoma cell [<xref rid="B65-nanomaterials-10-01072" ref-type="bibr">65</xref>]. Currently, there is an array of nanostructures, namely metal NPs, graphene oxide (GO), QDs, silica NPs, polymeric NPs, and carbon nanotubes, that are being seriously scrutinized for virus testing and detection [<xref rid="B66-nanomaterials-10-01072" ref-type="bibr">66</xref>,<xref rid="B67-nanomaterials-10-01072" ref-type="bibr">67</xref>,<xref rid="B68-nanomaterials-10-01072" ref-type="bibr">68</xref>]. The advancements in (nano)biohybrid structures are the common methods for exploiting NPs in virus detection, which can include biomolecules (one or more) derived from viruses. Antibody (Ab), DNA, RNA, antigen, etc. are conjugated on the surface of a diversity of NP forms which enable rapid, sensitive, direct, and facile detection with unprecedented multiplexing capabilities. The surface of Au NPs can effectively serve as soft metal ions, which simply binds to a soft ligand, e.g., thiols. The novel Au NP-based detection approaches have been developed for diverse types of clinically relevant viruses with a particular focus on the Au NP biohybrid systems, virus detection targets, and assay modalities. <xref rid="nanomaterials-10-01072-t003" ref-type="table">Table 3</xref> depicts diverse case studies employing several scanometric, electrochemical, fluorometric, or colorimetric systems in Au NP-based detection of viruses [<xref rid="B69-nanomaterials-10-01072" ref-type="bibr">69</xref>].</p><sec><title>Detection of SARS-CoV-2: Innovative Nano-Based Discoveries</title><p>The reverse transcription polymerase chain reaction (RT-PCR) has been generally deployed as a routine diagnosis method for the detection of CoVs [<xref rid="B70-nanomaterials-10-01072" ref-type="bibr">70</xref>]. However, some false-positive or false-negative reports have been observed, especially in the case of COVID-19. Interestingly, in one study, a double-operational plasmonic biosensor merging the localized surface plasmon resonance (LSPR) sensing transduction and the plasmonic photothermal (PPT) influence offered a promising substitute for the diagnosis of COVID-19, clinically. Delicate recognition of the particular arrangements of SARS-CoV-2 via nucleic acid hybridization has been accomplished using 2-D gold nano-islands decorated with complementary DNA receptors. The thermos-plasmonic heat was produced on the chip for improved sensing performance, whereby illumination at their plasmonic resonance frequency and the ensuing local PPT heat improved the in situ hybridization temperature and enabled the precise discernment of two similar gene sequences. This biosensor showed remarkable sensitivity for the examined SARS-CoV-2 sequences with a much lowered detection limit of 0.22 pM concentration and permitted specific target recognition in a multigene mixture [<xref rid="B70-nanomaterials-10-01072" ref-type="bibr">70</xref>]. Qui et al. [<xref rid="B70-nanomaterials-10-01072" ref-type="bibr">70</xref>] reported that by applying LSPR excited at two various wavelengths and the plasmonic resonances of PPT, remarkable stability, reliability, and sensitivity in diagnosis are achievable.</p><p>The detection of SARS-CoV-2 in medical samples could be accomplished by a field-effect transistor (FET)-based biosensing gadget, and its performance and efficacy was evaluated using cultured virus, antigen protein, and nasopharyngeal swab examples from COVID-19 patients (<xref ref-type="fig" rid="nanomaterials-10-01072-f004">Figure 4</xref>) [<xref rid="B71-nanomaterials-10-01072" ref-type="bibr">71</xref>]. For fabrication of the biosensor, the graphene sheets of the FET were coated with precise Ab against SARS-CoV-2 spike protein; the graphene sheets were decorated with the SARS-CoV-2 spike antibody through 1-pyrenebutyric acid <italic>N</italic>-hydroxysuccinimide ester as a probe linker. Accordingly, the produced FET tool could identify the SARS-CoV-2 spike protein at concentrations of 1 fg mL<sup>&#x02212;1</sup> in phosphate-buffered saline and 100 fg mL<sup>&#x02212;1</sup> medical transfer vehicle. Additionally, this sensor effectively identified SARS-CoV-2 in culture (with limit of detection ~1.6 &#x000d7; 101 pfu mL<sup>&#x02212;1</sup>) and medical tests (with limit of detection ~2.42 &#x000d7; 102 copies mL<sup>&#x02212;1</sup>). The prepared FET biosensor showed good sensitivity for diagnosis of COVID-19 with no sample pretreatment or labeling, but various other materials could be investigated to improve the signal-to-noise ratio [<xref rid="B71-nanomaterials-10-01072" ref-type="bibr">71</xref>].</p></sec></sec><sec id="sec2dot2-nanomaterials-10-01072"><title>2.2. Nanotechnology for Designing Vaccines</title><p>The disruptive outbreaks of fatal epidemics and respiratory infectious illnesses have greatly uplifted the progress of modern and effectual vaccine formulations to the status of a worldwide healthcare issue. It is generally known that prevention is invariably better than cure for the control of illnesses. Vaccination is still one of the most extraordinary tactics for preventing, controlling, or ameliorating infectious diseases, as well as administrating the antigenic materials to motivate an individual&#x02019;s immune systems to develop adaptive and protective immunity against a specific pathogen, especially viruses. To date, vaccination effectiveness has been extensively studied, and it has been authenticated that vaccines are responsible for the impressive control and even elimination of numerous potentially fatal illnesses, such as polio, smallpox, measles, hepatitis A, papilloma, etc. Despite numerous efforts, many other illnesses are still lacking therapeutic or effective prophylactic vaccines towards numerous clinically relevant viruses, e.g., HIV, Zika viruses, hepatitis C viruses (HCVs), influenza virus (e.g., H5N1, H1N1, etc.), cytomegaloviruses (CMV), Ebola viruses, RSV, and SARS-CoVs [<xref rid="B64-nanomaterials-10-01072" ref-type="bibr">64</xref>]. <xref ref-type="fig" rid="nanomaterials-10-01072-f005">Figure 5</xref> and <xref ref-type="fig" rid="nanomaterials-10-01072-f006">Figure 6</xref> present the general timelines for the vaccine development against viral infections [<xref rid="B72-nanomaterials-10-01072" ref-type="bibr">72</xref>], including the year when given viruses started transmitting in the human population, the start of clinical development of vaccines, and the employed technology that has been shown to work particularly well for a viral vector or nucleic acid-based vaccines. For HIV, in 1983 (the discovered year), only selected investigations that may be considered a major advance are shown. Similarly, 2003 illustrates the year H5N1 triggered several contagions, although H5N1 in humans was first registered in 1997.</p><p>The conventional vaccines have been produced utilizing inactivated/killed or live-attenuated organisms (first generation), whereas subunit and RNA/DNA vaccines (second and third generations, respectively) are applied to elicit protective immunity against contagious diseases [<xref rid="B77-nanomaterials-10-01072" ref-type="bibr">77</xref>,<xref rid="B78-nanomaterials-10-01072" ref-type="bibr">78</xref>,<xref rid="B79-nanomaterials-10-01072" ref-type="bibr">79</xref>,<xref rid="B80-nanomaterials-10-01072" ref-type="bibr">80</xref>,<xref rid="B81-nanomaterials-10-01072" ref-type="bibr">81</xref>]. Although subunit and DNA/RNA vaccines have several benefits, namely higher care profile, cost effectiveness, and capability to elicit an immune response against a particular pathogen over conventional vaccines, they suffer from challenges associated with the relatively weak immunogenicity, toxicity, intrinsic instability in vivo, and the requirement for multiple administration. These include the premature degradation of a molecule and the lack of ability to translate into an immunogen (e.g., proteins/peptides, lipids). Thus, there is an increasing need to develop a novel generation of vaccine molecules that can act as a functional immunogen and an adjuvant. Indeed, novel antigen preparations, new strategies for vaccination, as well as consecutive programs of general immunization have recently contributed to improvements in the efficacy of viral vaccines, amongst which the emerging nanotechnology holds enormous promise [<xref rid="B82-nanomaterials-10-01072" ref-type="bibr">82</xref>,<xref rid="B83-nanomaterials-10-01072" ref-type="bibr">83</xref>]. Furthermore, the frequency of boost, the administration routes, and refrigeration of the vaccines are still challenges for vaccine distribution in smaller and remote villages in some countries. To overcome such hurdles of subunit and conventional vaccines, nanotechnology-based formulations, NP-based vaccine candidates, and NP-based delivery systems with numerous advantages have been recently incorporated into vaccine development (<xref ref-type="fig" rid="nanomaterials-10-01072-f007">Figure 7</xref> and <xref rid="nanomaterials-10-01072-t004" ref-type="table">Table 4</xref>) [<xref rid="B24-nanomaterials-10-01072" ref-type="bibr">24</xref>].</p><p>A large number of nanostructured carriers, namely non-metal NPs, QDs, carbon nanomaterials, polymeric NPs (chitosan, PLGA (poly-lactide-<italic>co</italic>-glycolides), &#x003b3;-PGA (poly-&#x003b3;-glutamic acid), metal/metal oxide NPs, silica NPs, carbon black NPs, liposomes, dendrimers, solid lipid nanocarriers, and VLPs (virus like particles) have been intensively designed and investigated to carry a variety of molecules, e.g., drugs, proteins/peptides, DNA/RNA, antibodies, and vaccines for their utility in both antigen delivery (antigen nanocarriers) and as adjuvants to immune cells via an effective attempt to promote a protective humoral immune response. NPs and/or nanocarriers have been vastly studied as vaccine adjuvants since they possess structural and chemical features that increase their immunogenicity; synthesized NPs have illustrated their potential as nanovaccine delivery platforms (<xref rid="nanomaterials-10-01072-t005" ref-type="table">Table 5</xref>). In this respect, VLPs provide repetitive immunodominant viral epitopes to improve the activation of a particular, robust immune response comprising humoral or cellular immunities [<xref rid="B88-nanomaterials-10-01072" ref-type="bibr">88</xref>,<xref rid="B89-nanomaterials-10-01072" ref-type="bibr">89</xref>]; the first licensed VLP nanovaccine for human utility was the HBsAg (hepatitis B surface antigen). Nevertheless, the protective efficacy of nanocarrier/NPs against viruses that exploit diverse infection routes are required to be improved and better characterized. It is not clear whether a nasal or oral nanovaccine would achieve a better, long-lasting mucosal immunity or longer-term protection against a particular virus or whether a sufficient protection would ensue when administered via various routes or at different age groups. Nanocarrier/NP-based delivery systems can generally protect nanovaccines from premature degradation, increase stability, have excellent adjuvant properties, and may help in the targeted/controlled delivery of immunogens to antigen-presenting cells (APCs).</p><p>Incorporation of antigens in various NPs may be achieved via conjugation (covalent modifications) and/or by encapsulation (physical entrapment); these NPs incorporating antigens could exert local depot effects for ensuring the presentation of a specific antigen to immune cells [<xref rid="B111-nanomaterials-10-01072" ref-type="bibr">111</xref>]. Generally, the probability of drug encapsulation, modifications by polymers (e.g., polyethylene glycol (PEG), carbohydrates, among others), or modular functionalization by the fabrication of stable structures could all lead to improved drug delivery and optimized drug dosing via enhanced stability and drug retention times [<xref rid="B112-nanomaterials-10-01072" ref-type="bibr">112</xref>,<xref rid="B113-nanomaterials-10-01072" ref-type="bibr">113</xref>,<xref rid="B114-nanomaterials-10-01072" ref-type="bibr">114</xref>,<xref rid="B115-nanomaterials-10-01072" ref-type="bibr">115</xref>,<xref rid="B116-nanomaterials-10-01072" ref-type="bibr">116</xref>]. Immune cells generally express diverse surface receptors, namely the scavenger receptor, toll-like receptor, and mannose receptor [<xref rid="B117-nanomaterials-10-01072" ref-type="bibr">117</xref>]. Modifying the NPs/nanocarriers&#x02019; surfaces with a diversity of directing moieties (e.g., antibodies) allows the transport of viral antigens directly to particular surface receptors, thus inciting specific and selective mucosal or robust immune reactions. Indeed, NPs coated with immune cell-targeting molecules, such as antibodies, peptides, and carbohydrates [<xref rid="B118-nanomaterials-10-01072" ref-type="bibr">118</xref>,<xref rid="B119-nanomaterials-10-01072" ref-type="bibr">119</xref>,<xref rid="B120-nanomaterials-10-01072" ref-type="bibr">120</xref>], can be targeted with these overexpressed receptors to increase the adjuvant delivery and antigen efficacy for the promotion of a specific and selective or robust immune response in prophylactic nanovaccines.</p><sec><title>CoVs and Nanovaccines</title><p>Vaccination is generally the most cost-effective way and affordable strategy to prevent, control, and fight against infections, especially those leading to several respiratory or pulmonary diseases. To date, vaccine formulations include subunit protein antigens, live-attenuated viruses, or inactivated/killed pathogens, which can elicit an antigen-specific immune response. Conventionally, live-attenuated vaccines present a reversion risk to their pathogenic virulence under a certain immunocompromised condition, whereas inactivated vaccines mostly lead to weak immune responses. Some vaccines based on protein subunits have also been developed to overcome these problems. The formulations of these vaccines can suffer from a reduced immunogenicity, and the protection induced is largely partial. In response to these risks, it is immensely crucial to develop risk-free and effective new vaccines in conjunction with nanotechnology-driven drug delivery systems, an essential requirement to achieve desired cell-mediated immunity against specific infections. Recent vaccine development efforts have mainly focused on the CoV transmembrane spike (S) glycoprotein, which extends from the viral surface and mediates host cell entry [<xref rid="B121-nanomaterials-10-01072" ref-type="bibr">121</xref>]. SARS-CoV-2 S requires angiotensin-converting enzyme 2 (ACE2) to pass into cells. The receptor-binding areas of SARS-CoV S and SARS-CoV-2 S attach with similar affinities to human ACE2, thus causing the effective spread of SARS-CoV-2 in large human populations. SARS-CoV-2 S glycoprotein shelters a furin cleavage site at the margin of S1/S2 subunits, which distinguishes this virus from SARS-related CoVs and SARS-CoV. Additionally, SARS-CoV-2 S ectodomain trimer was chosen to provide a blueprint for designing vaccines and inhibitors of viral entrance. SARS-CoV S murine polyclonal antibodies effectively obstructed SARS-CoV-2 S mediated entrance in cells [<xref rid="B122-nanomaterials-10-01072" ref-type="bibr">122</xref>].</p><p>It has been shown that the vaccination of mice with CoV S NPs could produce remarkable amounts of neutralizing antibodies against the homologous virus, although cross-protection against the heterologous virus was not provided [<xref rid="B123-nanomaterials-10-01072" ref-type="bibr">123</xref>]. It was suggested that CoV S NPs are capable of provoking precise anti-MERS- and SARS-CoV antibody responses in mice; however, this does not provide the overall anti-CoV response for protection against multiple CoVs, and further studies should be undertaken regarding nanovaccines for these purposes. Some adjuvants can be employed to accelerate the generation of neutralizing antibodies to CoV S. For example, alum and matrix M1 were employed with a remarkable increase in neutralizing antibodies (Alum: 15 fold and Matrix M1: 68 fold) over the neutralizing antibody levels generated from S NPs alone. Alum is considered as typical adjuvant employed to increase the neutralizing antibodies for SARS-CoV in a VLP vaccine approach [<xref rid="B124-nanomaterials-10-01072" ref-type="bibr">124</xref>]; additionally, it remarkably increased responses to MERS-CoV S NPs and SARS-CoV S NPs in mice [<xref rid="B123-nanomaterials-10-01072" ref-type="bibr">123</xref>].</p><p>Innovative studies and further investigations are required to validate if CoV S NP vaccinations can block CoV pathogenesis and replication in vivo, and subsequent further evaluations could be undertaken in animal models [<xref rid="B125-nanomaterials-10-01072" ref-type="bibr">125</xref>]. In neutralization evaluations, low-level, non-specific neutralization activity of PBS-vaccinated mice was observed, although all adjuvanted MERS-CoV S NP vaccinated mice showed remarkably elevated corresponding activities. Additionally, Matrix-M1 adjuvant increased the anti-MERS-CoV S neutralizing antibody reaction in vaccinated mice. It was revealed that mice vaccinated with MERS-CoV S NPs with Matrix-M1 were capable of proficiently and entirely blocking MERS-CoV replication in lungs; the Matrix-M1 NP with MERS-CoV S was a major candidate in terms of additional advancements for applications in humans or camels [<xref rid="B125-nanomaterials-10-01072" ref-type="bibr">125</xref>].</p><p>In one study, two kinds of vaccines for MERS-CoV were investigated, which included spike protein NPs prepared with alum adjuvant and recombinant adenovirus serotype 5 encoding the MERS-CoV spike gene (Ad5/MERS) [<xref rid="B87-nanomaterials-10-01072" ref-type="bibr">87</xref>]. These vaccines stimulated precise immunoglobulin G against MERS-CoV, although neutralizing antibodies against MERS-CoV were stimulated solely by homologous and heterologous prime-boost immunizations with spike protein NPs. Remarkably, the activation of Th1 cells was stimulated by immunization programs containing Ad5/MERS, but not by those containing spike protein NPs alone [<xref rid="B87-nanomaterials-10-01072" ref-type="bibr">87</xref>]. Heterologous prime-boost vaccination schedules comprising Ad5/MERS provoked concurrent Th1 and Th2 reactions, while homologous prime-boost schedules did not. Therefore, heterologous prime-boost might stimulate prolonged immune reactions against MERS-CoV due to a proper balance of Th1/Th2 responses [<xref rid="B87-nanomaterials-10-01072" ref-type="bibr">87</xref>]. However, both of these vaccination approaches could offer defense from MERS-CoV challenge in mice; a heterologous approach by priming with Ad5/MERS and boosting with spike protein NPs may be a promising and effective prophylactic approach against MERS-CoV infection [<xref rid="B87-nanomaterials-10-01072" ref-type="bibr">87</xref>].</p><p>In one investigation, by expressing the structural proteins of MERS-CoV in silkworm larvae and Bm5 cells, some vaccine candidates were prepared. Consequently, the spike S protein of MERS-CoV came up short on its transmembrane, and the cytoplasmic areas (S&#x00394;TM) were discharged into the hemolymph of silkworm larvae utilizing a bombyxin signal peptide and refined by applying affinity chromatography. The purified S&#x00394;TM generated small NPs as well as the full-length S protein and displayed the capability of binding to human dipeptidyl peptidase 4 (a receptor of MERS-CoV) [<xref rid="B126-nanomaterials-10-01072" ref-type="bibr">126</xref>], thus revealing that bioactive S&#x00394;TM could express in silkworm larvae. For the production of MERS-CoV-like particles, the co-expression of spike proteins has been completed in Bm5 cells, and envelope (E) and membrane (M) proteins secreted E and M proteins extracellularly, signifying that MERS-CoV-LPs might be generated. Although S protein has not been detected on virus-like particles (VLPs), E and M proteins have been located in the culture supernatant; S protein-displaying nanovesicles (~100&#x02013;200 nm) were formed and confirmed by immuno-transmission electron microscopy (TEM). These purified S&#x00394;TM can be deployed to produce innovative NP-based vaccines against CoVs and in diagnostic detecting approaches [<xref rid="B126-nanomaterials-10-01072" ref-type="bibr">126</xref>].</p><p>In the process of vaccination, the utilizing of vaccine adjuvants and follow-up evaluations are very critical. For instance, silver NPs can be deployed as an adjuvant in mucosal vaccines based on inactivated influenza virus, which stimulates the remarkable antigen specific IgA formation with low toxicity by stimulating bronchus-associated lymphoid tissue (BALT) neogenesis [<xref rid="B127-nanomaterials-10-01072" ref-type="bibr">127</xref>]. Additionally, in one study, gold NPs and toll-like receptor agonists (applied as operative adjuvant in UV-inactivated SARS&#x02013;CoV vaccine) were investigated as vaccine adjuvants for application with recombinant S protein [<xref rid="B50-nanomaterials-10-01072" ref-type="bibr">50</xref>]. Consequently, the immunization of mice was accomplished with more than 0.5&#x02009;&#x000b5;g S protein without escape of adjuvant from SARS after infection with mouse-adapted SARS&#x02013;CoV; however, eosinophilic infiltrations were detected in the lungs of the mice with immunization [<xref rid="B50-nanomaterials-10-01072" ref-type="bibr">50</xref>]. It was observed that gold NP-adjuvanted protein stimulated remarkable response of IgG but was unsuccessful in improving the efficiency of vaccine or reducing eosinophilic infiltration, due to significantly allergic inflammatory responses. While comparable virus titers have been detected in control animals and animals immunized with S protein with or without gold NPs, Type 1 interferon and pro-inflammatory replies were reasonable in the mice treated with S protein with and without gold NPs. Additionally, the Toll-like receptor agonist-adjuvanted vaccine triggered remarkable protective antibodies deprived of eosinophilic infiltrations, in addition to responses of Th1/17 cytokine [<xref rid="B50-nanomaterials-10-01072" ref-type="bibr">50</xref>].</p></sec></sec><sec id="sec2dot3-nanomaterials-10-01072"><title>2.3. QDs and GO against CoVs Infections</title><p>QDs can be employed as perfect alternatives against pathogenic human CoVs infections; it is a very challenging issue, because these viruses vary biologically and can quickly change. In one investigation, the antiviral activities of seven different carbon quantum dots (CQDs) for treating human CoV HCoV-229E contagions were evaluated. The CQDs, about 10 nm in size with remarkable solubility in water, were synthesized via hydrothermal carbonization of carbon precursors, citric acid/ethylenediamine, and post-synthetic modification deploying boronic acids; concentration-dependent virus inactivation (EC50 of 52 &#x000b1; 8 &#x003bc;g mL<sup>&#x02212;1</sup>) was discernible from these ensuing nanomaterials [<xref rid="B57-nanomaterials-10-01072" ref-type="bibr">57</xref>]. Additionally, CQDs were also prepared from 4-aminophenylboronic acid with no additional modifications with much lowered EC50 of 5.2 &#x000b1; 0.7 &#x003bc;g mL<sup>&#x02212;1</sup>. Suggested mechanisms revealed that the HCoV-229E entrance inhibition is possibly due to the interaction of the functional groups of the CQDs with entry receptors of HCoV-229E; additionally, the viral replication step also displayed similarly big inhibition activity (<xref ref-type="fig" rid="nanomaterials-10-01072-f008">Figure 8</xref>) [<xref rid="B57-nanomaterials-10-01072" ref-type="bibr">57</xref>].</p><p>For detection of CoVs, some innovative approaches have focused on application of QDs. As an example, chiral zirconium QDs were prepared using <italic>L</italic>(+)-ascorbic acid, which showed fluorescence and circular dichroism characteristics [<xref rid="B53-nanomaterials-10-01072" ref-type="bibr">53</xref>]. The cytotoxicity of the prepared QDs was evaluated against rat brain glioma C6 cells using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The anti-infectious bronchitis virus (IBV) antibodies of CoV were linked to these QDs to produce an immuno-link at the existence of anti-IBV antibody-conjugated magneto-plasmonic NPs and the target analyte. The fluorescence characteristics of the nanohybrids (immuno-conjugated QD-magneto-plasmonic NPs) via the external magnetic field-prompted partition process provided biosensing of CoVs (detection limit being: 79.15 EID/50 &#x003bc;L) (<xref ref-type="fig" rid="nanomaterials-10-01072-f009">Figure 9</xref>) [<xref rid="B53-nanomaterials-10-01072" ref-type="bibr">53</xref>].</p><p>The wide-spectrum antiviral activities of graphene oxide (GO) against the porcine epidemic diarrhea virus (PEDV, an RNA virus) and pseudorabies virus (PRV, a DNA virus) have been evaluated; GO remarkably inhibited the infection of these viruses, at non-cytotoxic concentrations, for a 2 log diminution in virus titers [<xref rid="B128-nanomaterials-10-01072" ref-type="bibr">128</xref>]. Importantly, GO showed effective antiviral activities when linked with PVP, a nonionic oligomer, however not when linked with a cationic polymer, poly (diallyldimethylammonium chloride) (PDDA). Moreover, graphite and GO demonstrated poorer antiviral activity than monolayer GO and reduced graphene oxide (RGO), signifying that the nano-sheet constitution is crucial for antiviral characteristics. Importantly, GO incapacitated the viruses by structural damage before the virus could enter into cells [<xref rid="B128-nanomaterials-10-01072" ref-type="bibr">128</xref>]. In another investigation, Ag NP-modified GO nanocomposites, self-accumulated via electrostatic energy, were employed to inhibit entry into host cells for respiratory syndrome and porcine reproductive virus (~59% inhibition). Additionally, this nanocomposite prescription obstructed virus proliferation by accelerating the formation of IFN-stimulating genes (ISGs) and interferon-&#x003b1; (IFN-&#x003b1;) [<xref rid="B129-nanomaterials-10-01072" ref-type="bibr">129</xref>]. It appears that these nanomaterials can be considered as promising antiviral agents and should be further investigated for CoVs, especially SARS-CoV-2.</p></sec></sec><sec id="sec3-nanomaterials-10-01072"><title>3. Current Challenges and Future Prospects</title><p>The incorporation of nanoscience for infectious disease treatment offers novel opportunities to overcome existing challenges of conventional drug therapies and presents therefore massive potential towards the enhanced mechanisms of action of recently accessible pharmaceuticals or the advancement of novel nano-therapeutics and diagnostics that are urgently needed in the drug resistance age. NPs/nanocarriers or nanovaccines (especially nanostructures functionalized with proper functional groups) could be effectively designed to integrate traditional antiviral features with those amendments. Such alterations are distinctive of advanced nanosystems with a high/large surface-volume ratio, ultra-small size, and the potential abilities for tailoring the surface with the multi-functionalization probability. Thus, they could be applied to interface with numerous viruses along with preventing their entrance into cells/tissues.</p><p>Generally, from the management point to the site of antiviral activities, pharmaceuticals may encounter a diversity of biological barriers [<xref rid="B130-nanomaterials-10-01072" ref-type="bibr">130</xref>,<xref rid="B131-nanomaterials-10-01072" ref-type="bibr">131</xref>,<xref rid="B132-nanomaterials-10-01072" ref-type="bibr">132</xref>]. One main instance is the setting up of latent reservoirs in cellular and structurally immune-privileged sites, for example, the blood-brain or blood-testis barrier. Therapeutic size is a pivotal consideration in successful drug development for transmissible diseases, where entrance to unreachable compartments, namely viruses crossing the blood-brain barrier, is obligatory for preventing the creation of dormant infections with persistent replication at low levels [<xref rid="B133-nanomaterials-10-01072" ref-type="bibr">133</xref>]. Nanoparticulate drug transporters are generally proficient at crossing such membranes and are thus a favorable means to be studied for avoiding this impediment. The utilization of NPs or nanocarriers to ease entrance into diverse subcellular sections is consequently an outstanding choice because of their small size, architecture, or specific properties; they have been therefore developed for viral detection or treatment and are adequately capable of surmounting natural obstructions to attain specific and targeted delivery [<xref rid="B9-nanomaterials-10-01072" ref-type="bibr">9</xref>].</p><p>Nanomaterials have recently appeared to exert their antiviral activities against viruses by different mechanisms, making them attractive tools for viral treatment. All immunological assets and benefits of nanostructures can ensue from the combination of the following features: (i) surface charge tenability (that could assist cellular entrance/export through the cell membrane) [<xref rid="B134-nanomaterials-10-01072" ref-type="bibr">134</xref>], (ii) small particle size (to enable drug transfer into immune-favored locations) [<xref rid="B21-nanomaterials-10-01072" ref-type="bibr">21</xref>,<xref rid="B112-nanomaterials-10-01072" ref-type="bibr">112</xref>], (iii) large surface area (to ensure that they can accommodate the large drug payloads) [<xref rid="B113-nanomaterials-10-01072" ref-type="bibr">113</xref>], and (iv) intrinsic antiviral assets (that can display biomimetic properties) [<xref rid="B135-nanomaterials-10-01072" ref-type="bibr">135</xref>,<xref rid="B136-nanomaterials-10-01072" ref-type="bibr">136</xref>], for example, dendrimers and silver NPs [<xref rid="B137-nanomaterials-10-01072" ref-type="bibr">137</xref>,<xref rid="B138-nanomaterials-10-01072" ref-type="bibr">138</xref>].</p><p>Besides these, nanostructures possess other exceptional properties, namely their capability to deliver viral antigens in a controlled manner, their capacities to mimic the viruses in terms of structure or size without requiring a real infection, and their capabilities to activate follicular dendritic cells or B cells, antigen cross-presentation, as well as induce a humoral/cellular immune response. Collectively, the clinical applications of NP-based therapeutics are revolutionizing several medical fields, namely diagnosis, treatment, control/management, prevention, and detection, such as nanocarriers for viral infections and delivery of nanodrugs or bioactive compounds. Consequently, nanodrug delivery can be immensely improved by these nanostructures with the desired directing entities to enhance specificities for preferred target tissues, cell types, or subcellular compartments [<xref rid="B134-nanomaterials-10-01072" ref-type="bibr">134</xref>,<xref rid="B139-nanomaterials-10-01072" ref-type="bibr">139</xref>]. Indeed, some approved nanodrug delivery systems and nanovaccines are making an actual revolution in viral disease prevention, treatment, and management; nanotechnology offers new prospects towards the manufacturing of vaccine nanoformulations [<xref rid="B140-nanomaterials-10-01072" ref-type="bibr">140</xref>,<xref rid="B141-nanomaterials-10-01072" ref-type="bibr">141</xref>].</p><p>NP-based vaccines (or nanovaccines) are envisaged to be more effective, safe, economic, or convenient than subunit and conventional vaccines. Nanovaccines may provide an excellent future ahead if the following goals are attained: (i) stabilization at ambient temperature via encapsulation of vaccines in NPs, (ii) exploration of replaceable/interchangeable routes of administration, and (iii) facilitation of controlled/specific release at a particular location. They may be reinforced once, unlike conventional vaccines which are generally required to be reinforced many times. Indeed, nanotechnology platforms afford a new choice and a promising opportunity to improve cellular or humoral immune responses; nanovaccines may be induced either by cellular immunity (cytotoxic or helper T-cell responses) or humoral immunity (B-cell responses). The advantages are ascribable to the nanoscale particle size that can facilitate uptake via phagocytic cells and the mucosa/gut-associated lymphoid tissues, leading to efficient antigen processing and recognition.</p><p>One of the probable methodologies could be based on the utilization of NP-based vaccination [<xref rid="B142-nanomaterials-10-01072" ref-type="bibr">142</xref>]. Nanotechnology presents diverse benefits in the areas of detection, management, and treatment, either via site-specific drug delivery or targeted delivery of particular medicines in a controlled manner. Nanoscience has been recently applied to improve and develop vaccine efficacy as well as optimization utilizing several advanced nanosystems to improve antigen delivery and efficient induction of humoral/cellular immunity [<xref rid="B143-nanomaterials-10-01072" ref-type="bibr">143</xref>,<xref rid="B144-nanomaterials-10-01072" ref-type="bibr">144</xref>]. One of the most crucial advantages of using NPs in vaccine systems is that they could deliver proteins and peptides to specific tissue cells and help them to produce a robust immune response [<xref rid="B144-nanomaterials-10-01072" ref-type="bibr">144</xref>,<xref rid="B145-nanomaterials-10-01072" ref-type="bibr">145</xref>]. Indeed, these NPs can protect the applied antigens from premature proteolytic or enzymatic degradation, control release, simplify antigen uptake, and are safe for human consumption. For some viruses, including SARS-CoVs, RSV, and acquired immunodeficiency syndrome (HIV/AIDS), no effective vaccines are presently accessible making infection detection and treatment a critical necessity. Today, three viruses, namely MERS- and SARS-CoVs, and SARS-CoV-2, present key ultimatums for management since there are still no specific anti-CoV drugs accessible. Owing to the involvement of COVID-19, many facts regarding virulence, pathogenesis, and the real source of viral infection or mode of transmission still need to be addressed; some suggestions and potential alternatives for further evaluations, especially for SARS-CoV-2, include:
<list list-type="bullet"><list-item><p>The effects of metallic NPs (e.g., silver, gold and copper NPs or hybrid nanomaterials) can be evaluated against SARS-CoV-2 [<xref rid="B17-nanomaterials-10-01072" ref-type="bibr">17</xref>]. For instance, silver NPs showed inhibition abilities against the viral entrance in host cells, for HIV-1 virus, as these NPs are capable of interacting with the cell receptors [<xref rid="B146-nanomaterials-10-01072" ref-type="bibr">146</xref>]. Additionally, gold NPs stabilized by biocompatible polymers demonstrated antiviral activity against HIV-1 and some subtypes of influenza virus (e.g., H1N1, H3N2, H5N1) [<xref rid="B17-nanomaterials-10-01072" ref-type="bibr">17</xref>,<xref rid="B146-nanomaterials-10-01072" ref-type="bibr">146</xref>].</p></list-item><list-item><p>QDs, metal-grafted GO, nanocomposites (e.g., CuO nanocomposites), and nano-phytotherapeutics can be considered for their potential antiviral evaluations [<xref rid="B17-nanomaterials-10-01072" ref-type="bibr">17</xref>,<xref rid="B147-nanomaterials-10-01072" ref-type="bibr">147</xref>].</p></list-item><list-item><p>Biodegradable nanocarriers and carbon nanotubes can be proposed as potential antiviral agent carriers. For instance, antiviral drugs such as ribavirin and isoprinosine have been chemically linked on a single-walled carbon nanotube surface to transmit these antiviral compounds across biological membranes [<xref rid="B148-nanomaterials-10-01072" ref-type="bibr">148</xref>].</p></list-item><list-item><p>Multi-functionalization should be performed for drug delivery platforms, imaging, and detection systems for viral localization and specific tissue or organ targeting. Development of toxicity and the reduction of side effects as well as bioavailability of antiviral drugs can be further explored based on nanotechnological insights; nanotrap particles showed suitable inhibition effects against influenza viruses, which can be explored for other viruses [<xref rid="B149-nanomaterials-10-01072" ref-type="bibr">149</xref>].</p></list-item><list-item><p>Importantly, multidrug NPs (with high biocompatibility and drug loading) for the mitigation of uncontrolled inflammation is very promising, especially in the case of COVID-19. In one study, NPs were produced by conjugating squalene, an endogenous lipid, with adenosine, an endogenous immuno-modulator, and then encapsulating &#x003b1;-tocopherol, a natural antioxidant [<xref rid="B150-nanomaterials-10-01072" ref-type="bibr">150</xref>]. By using the vascular endothelial barrier dysfunction at sites of acute inflammation, these multidrug NPs could transport the therapeutic agents in a targeted manner and confer remarkable survival advantages to the treated animals in lethal models of endotoxemia. The selective delivery of adenosine and antioxidants together could serve as an innovative method for the treatment of acute inflammation with reduced side effects and significant therapeutic potential, especially in the case of cytokine storm (hypercytokinaemia) ensued by COVID-19 [<xref rid="B150-nanomaterials-10-01072" ref-type="bibr">150</xref>].</p></list-item><list-item><p>Rapid and reliable tests for the new CoV are critical for controlling the pandemic, such as innovative biosensors designed for SARS-CoV-2 detection by applying nano-based technology; the aforementioned biosensor designed by Qui et al. [<xref rid="B70-nanomaterials-10-01072" ref-type="bibr">70</xref>] is an example of such.</p></list-item></list></p></sec><sec sec-type="conclusions" id="sec4-nanomaterials-10-01072"><title>4. Conclusions</title><p>Nanomaterials can be considered as perfect candidates against viral infections, especially CoVs, because of their ability to enter cells easily and interact with viruses and avoid viral genome replication. NPs can be applied as a measure to revert antiviral resistance, which is a gradually developing challenge of conventional therapeutics presently available. Furthermore, improvements, especially enhancing the bioavailability and reducing the toxicity of conventional antiviral drugs, can be executed by using groundbreaking advancements in nanotechnology. Nowadays, researchers are focusing on high-level experimental studies to find innovative and smart nano/bio-materials and matrices for designing controlled release and targeted drug delivery systems; nanovaccines and nano/bio-sensors against pathogenic viruses, particularly for human and animal CoVs, need more exploration. In the history of mankind, different cases of epidemics and pandemics have claimed the lives of many people. In the meantime, however, power to control a crisis, innovative solutions, intelligent management, and the use of smart and modern technologies, especially exploiting the field of emerging nanotechnology, could be very effective in managing the current and future outbreaks.</p></sec></body><back><notes><title>Author Contributions</title><p>All authors contributed to writing of original draft. M.N., S.I. and R.S.V. conceptualization; writing&#x02014;review and editing. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>The study was self-funded.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><notes><title>Financial Disclosure</title><p>There is no financial disclosure.</p></notes><ref-list><title>References</title><ref id="B1-nanomaterials-10-01072"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>R.E.</given-names></name><name><surname>Ma</surname><given-names>W.</given-names></name><name><surname>Richt</surname><given-names>J.A.</given-names></name></person-group><article-title>Swine and influenza: A challenge to one health research</article-title><source>Influenza Pathogenesis and Control-Volume I.</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin, Germany</publisher-loc><year>2014</year><fpage>205</fpage><lpage>218</lpage></element-citation></ref><ref id="B2-nanomaterials-10-01072"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qasim</surname><given-names>M.</given-names></name><name><surname>Lim</surname><given-names>D.-J.</given-names></name><name><surname>Park</surname><given-names>H.</given-names></name><name><surname>Na</surname><given-names>D.</given-names></name></person-group><article-title>Nanotechnology for diagnosis and treatment of infectious diseases</article-title><source>J. Nanosci. Nanotechnol.</source><year>2014</year><volume>14</volume><fpage>7374</fpage><lpage>7387</lpage><pub-id pub-id-type="doi">10.1166/jnn.2014.9578</pub-id><?supplied-pmid 25942798?><pub-id pub-id-type="pmid">25942798</pub-id></element-citation></ref><ref id="B3-nanomaterials-10-01072"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wejse</surname><given-names>C.</given-names></name><name><surname>Patsche</surname><given-names>C.B.</given-names></name><name><surname>K&#x000fc;hle</surname><given-names>A.</given-names></name><name><surname>Bamba</surname><given-names>F.J.V.</given-names></name><name><surname>Mendes</surname><given-names>M.S.</given-names></name><name><surname>Lemvik</surname><given-names>G.</given-names></name><name><surname>Gomes</surname><given-names>V.F.</given-names></name><name><surname>Rudolf</surname><given-names>F.</given-names></name></person-group><article-title>Impact of HIV-1, HIV-2, and HIV-1+ 2 dual infection on the outcome of tuberculosis</article-title><source>Int. J. Infect. Dis.</source><year>2015</year><volume>32</volume><fpage>128</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2014.12.015</pub-id><?supplied-pmid 25499041?><pub-id pub-id-type="pmid">25499041</pub-id></element-citation></ref><ref id="B4-nanomaterials-10-01072"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braden</surname><given-names>C.R.</given-names></name><name><surname>Dowell</surname><given-names>S.F.</given-names></name><name><surname>Jernigan</surname><given-names>D.B.</given-names></name><name><surname>Hughes</surname><given-names>J.M.</given-names></name></person-group><article-title>Progress in global surveillance and response capacity 10 years after severe acute respiratory syndrome</article-title><source>Emerg. Infect. Dis.</source><year>2013</year><volume>19</volume><fpage>864</fpage><pub-id pub-id-type="doi">10.3201/eid1906.130192</pub-id><?supplied-pmid 23731871?><pub-id pub-id-type="pmid">23731871</pub-id></element-citation></ref><ref id="B5-nanomaterials-10-01072"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>World Health Statistics 2016: Monitoring Health for the SDGs Sustainable Development Goals</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2016</year></element-citation></ref><ref id="B6-nanomaterials-10-01072"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kutter</surname><given-names>J.S.</given-names></name><name><surname>Spronken</surname><given-names>M.I.</given-names></name><name><surname>Fraaij</surname><given-names>P.L.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.M.</given-names></name><name><surname>Herfst</surname><given-names>S.</given-names></name></person-group><article-title>Transmission routes of respiratory viruses among humans</article-title><source>Curr. Opin. Virol.</source><year>2018</year><volume>28</volume><fpage>142</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2018.01.001</pub-id><pub-id pub-id-type="pmid">29452994</pub-id></element-citation></ref><ref id="B7-nanomaterials-10-01072"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavia</surname><given-names>A.T.</given-names></name></person-group><article-title>Viral infections of the lower respiratory tract: Old viruses, new viruses, and the role of diagnosis</article-title><source>Clin. Infect. Dis.</source><year>2011</year><volume>52</volume><fpage>S284</fpage><lpage>S289</lpage><pub-id pub-id-type="doi">10.1093/cid/cir043</pub-id><pub-id pub-id-type="pmid">21460286</pub-id></element-citation></ref><ref id="B8-nanomaterials-10-01072"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>T.A.</given-names></name><name><surname>Khurana</surname><given-names>S.</given-names></name><name><surname>Tilden</surname><given-names>S.J.</given-names></name></person-group><article-title>Viral respiratory infections</article-title><source>Pediatric Clin. North Am.</source><year>1994</year><volume>41</volume><fpage>1365</fpage><lpage>1381</lpage><pub-id pub-id-type="doi">10.1016/S0031-3955(16)38876-9</pub-id></element-citation></ref><ref id="B9-nanomaterials-10-01072"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cojocaru</surname><given-names>F.-D.</given-names></name><name><surname>Botezat</surname><given-names>D.</given-names></name><name><surname>Gardikiotis</surname><given-names>I.</given-names></name><name><surname>Uritu</surname><given-names>C.-M.</given-names></name><name><surname>Dodi</surname><given-names>G.</given-names></name><name><surname>Trandafir</surname><given-names>L.</given-names></name><name><surname>Rezus</surname><given-names>C.</given-names></name><name><surname>Rezus</surname><given-names>E.</given-names></name><name><surname>Tamba</surname><given-names>B.-I.</given-names></name><name><surname>Mihai</surname><given-names>C.-T.</given-names></name></person-group><article-title>Nanomaterials designed for antiviral drug delivery transport across biological barriers</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>171</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12020171</pub-id></element-citation></ref><ref id="B10-nanomaterials-10-01072"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>S.S.Y.</given-names></name><name><surname>Yuen</surname><given-names>K.-Y.</given-names></name></person-group><article-title>The management of coronavirus infections with particular reference to SARS</article-title><source>J. Antimicrob. Chemother.</source><year>2008</year><volume>62</volume><fpage>437</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1093/jac/dkn243</pub-id><pub-id pub-id-type="pmid">18565970</pub-id></element-citation></ref><ref id="B11-nanomaterials-10-01072"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Principi</surname><given-names>N.</given-names></name><name><surname>Piralla</surname><given-names>A.</given-names></name><name><surname>Zampiero</surname><given-names>A.</given-names></name><name><surname>Bianchini</surname><given-names>S.</given-names></name><name><surname>Umbrello</surname><given-names>G.</given-names></name><name><surname>Scala</surname><given-names>A.</given-names></name><name><surname>Bosis</surname><given-names>S.</given-names></name><name><surname>Fossali</surname><given-names>E.</given-names></name><name><surname>Baldanti</surname><given-names>F.</given-names></name><name><surname>Esposito</surname><given-names>S.</given-names></name></person-group><article-title>Bocavirus infection in otherwise healthy children with respiratory disease</article-title><source>PLoS ONE</source><year>2015</year><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0135640</pub-id></element-citation></ref><ref id="B12-nanomaterials-10-01072"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorbalenya</surname><given-names>A.E.</given-names></name><name><surname>Baker</surname><given-names>S.C.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name><name><surname>de Groot</surname><given-names>R.J.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Gulyaeva</surname><given-names>A.A.</given-names></name><name><surname>Haagmans</surname><given-names>B.I.</given-names></name><name><surname>Iauber</surname><given-names>C.</given-names></name><name><surname>Ieontovich</surname><given-names>A.M.</given-names></name><name><surname>Neuman</surname><given-names>B.W.</given-names></name><etal/></person-group><article-title>The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2</article-title><source>Nat. Microbiol.</source><year>2020</year><fpage>5</fpage><pub-id pub-id-type="doi">10.1038/s41564-41020-40695-z</pub-id></element-citation></ref><ref id="B13-nanomaterials-10-01072"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Branche</surname><given-names>A.R.</given-names></name><name><surname>Falsey</surname><given-names>A.R.</given-names></name></person-group><article-title>Parainfluenza virus infection</article-title><source>Semin. Resp. Crit. Care Med.</source><year>2016</year><fpage>538</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1055/s-0036-1584798</pub-id><?supplied-pmid 27486735?><pub-id pub-id-type="pmid">27486735</pub-id></element-citation></ref><ref id="B14-nanomaterials-10-01072"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazur</surname><given-names>N.I.</given-names></name><name><surname>Higgins</surname><given-names>D.</given-names></name><name><surname>Nunes</surname><given-names>M.C.</given-names></name><name><surname>Melero</surname><given-names>J.A.</given-names></name><name><surname>Langedijk</surname><given-names>A.C.</given-names></name><name><surname>Horsley</surname><given-names>N.</given-names></name><name><surname>Buchholz</surname><given-names>U.J.</given-names></name><name><surname>Openshaw</surname><given-names>P.J.</given-names></name><name><surname>McLellan</surname><given-names>J.S.</given-names></name><name><surname>Englund</surname><given-names>J.A.</given-names></name></person-group><article-title>The respiratory syncytial virus vaccine landscape: Lessons from the graveyard and promising candidates</article-title><source>Lancet Infect. Dis.</source><year>2018</year><volume>18</volume><fpage>e295</fpage><lpage>e311</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30292-5</pub-id><pub-id pub-id-type="pmid">29914800</pub-id></element-citation></ref><ref id="B15-nanomaterials-10-01072"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>M.-P.</given-names></name><name><surname>Ma</surname><given-names>L.-Y.</given-names></name><name><surname>Zheng</surname><given-names>Q.</given-names></name><name><surname>Dong</surname><given-names>L.-L.</given-names></name><name><surname>Chen</surname><given-names>Z.-M.</given-names></name></person-group><article-title>Clinical characteristics of adenovirus associated lower respiratory tract infection in children</article-title><source>World J. Pediatrics</source><year>2013</year><volume>9</volume><fpage>346</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1007/s12519-013-0431-3</pub-id><?supplied-pmid 24235068?><pub-id pub-id-type="pmid">24235068</pub-id></element-citation></ref><ref id="B16-nanomaterials-10-01072"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munster</surname><given-names>V.J.</given-names></name><name><surname>Koopmans</surname><given-names>M.</given-names></name><name><surname>van Doremalen</surname><given-names>N.</given-names></name><name><surname>van Riel</surname><given-names>D.</given-names></name><name><surname>de Wit</surname><given-names>E.</given-names></name></person-group><article-title>A novel coronavirus emerging in China&#x02014;key questions for impact assessment</article-title><source>New Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>692</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1056/NEJMp2000929</pub-id><?supplied-pmid 31978293?><pub-id pub-id-type="pmid">31978293</pub-id></element-citation></ref><ref id="B17-nanomaterials-10-01072"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sportelli</surname><given-names>M.C.</given-names></name><name><surname>Izzi</surname><given-names>M.</given-names></name><name><surname>Kukushkina</surname><given-names>E.A.</given-names></name><name><surname>Hossain</surname><given-names>S.I.</given-names></name><name><surname>Picca</surname><given-names>R.A.</given-names></name><name><surname>Ditaranto</surname><given-names>N.</given-names></name><name><surname>Cioffi</surname><given-names>N.</given-names></name></person-group><article-title>Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2?</article-title><source>Nanomaterials</source><year>2020</year><volume>10</volume><elocation-id>802</elocation-id><pub-id pub-id-type="doi">10.3390/nano10040802</pub-id></element-citation></ref><ref id="B18-nanomaterials-10-01072"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>F.</given-names></name></person-group><article-title>Developing new antiviral agents for influenza treatment: What does the future hold?</article-title><source>Clin. Infect. Dis.</source><year>2009</year><volume>48</volume><fpage>S3</fpage><lpage>S13</lpage><pub-id pub-id-type="doi">10.1086/591851</pub-id><pub-id pub-id-type="pmid">19067613</pub-id></element-citation></ref><ref id="B19-nanomaterials-10-01072"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Little</surname><given-names>S.J.</given-names></name><name><surname>Holte</surname><given-names>S.</given-names></name><name><surname>Routy</surname><given-names>J.-P.</given-names></name><name><surname>Daar</surname><given-names>E.S.</given-names></name><name><surname>Markowitz</surname><given-names>M.</given-names></name><name><surname>Collier</surname><given-names>A.C.</given-names></name><name><surname>Koup</surname><given-names>R.A.</given-names></name><name><surname>Mellors</surname><given-names>J.W.</given-names></name><name><surname>Connick</surname><given-names>E.</given-names></name><name><surname>Conway</surname><given-names>B.</given-names></name></person-group><article-title>Antiretroviral-drug resistance among patients recently infected with HIV</article-title><source>N. Engl. J. Med.</source><year>2002</year><volume>347</volume><fpage>385</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa013552</pub-id><pub-id pub-id-type="pmid">12167680</pub-id></element-citation></ref><ref id="B20-nanomaterials-10-01072"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maseko</surname><given-names>S.B.</given-names></name><name><surname>Natarajan</surname><given-names>S.</given-names></name><name><surname>Sharma</surname><given-names>V.</given-names></name><name><surname>Bhattacharyya</surname><given-names>N.</given-names></name><name><surname>Govender</surname><given-names>T.</given-names></name><name><surname>Sayed</surname><given-names>Y.</given-names></name><name><surname>Maguire</surname><given-names>G.E.M.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Kruger</surname><given-names>H.G.</given-names></name></person-group><article-title>Purification and characterization of naturally occurring HIV-1 (South African subtype C) protease mutants from inclusion bodies</article-title><source>Protein Expr. Purif.</source><year>2016</year><volume>122</volume><fpage>90</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2016.02.013</pub-id><?supplied-pmid 26917227?><pub-id pub-id-type="pmid">26917227</pub-id></element-citation></ref><ref id="B21-nanomaterials-10-01072"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parboosing</surname><given-names>R.</given-names></name><name><surname>Maguire</surname><given-names>G.E.M.</given-names></name><name><surname>Govender</surname><given-names>P.</given-names></name><name><surname>Kruger</surname><given-names>H.G.</given-names></name></person-group><article-title>Nanotechnology and the treatment of HIV infection</article-title><source>Viruses</source><year>2012</year><volume>4</volume><fpage>488</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.3390/v4040488</pub-id><pub-id pub-id-type="pmid">22590683</pub-id></element-citation></ref><ref id="B22-nanomaterials-10-01072"><label>22.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Nasrollahzadeh</surname><given-names>M.</given-names></name><name><surname>Sajadi</surname><given-names>S.M.</given-names></name><name><surname>Sajjadi</surname><given-names>M.</given-names></name><name><surname>Issaabadi</surname><given-names>Z.</given-names></name></person-group><article-title>An Introduction to Nanotechnology</article-title><source>Interface Science and Technology</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2019</year><volume>Volume 28</volume><fpage>1</fpage><lpage>27</lpage></element-citation></ref><ref id="B23-nanomaterials-10-01072"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moghimi</surname><given-names>S.M.</given-names></name><name><surname>Hunter</surname><given-names>A.C.</given-names></name><name><surname>Murray</surname><given-names>J.C.</given-names></name></person-group><article-title>Nanomedicine: Current status and future prospects</article-title><source>FASEB J.</source><year>2005</year><volume>19</volume><fpage>311</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1096/fj.04-2747rev</pub-id><?supplied-pmid 15746175?><pub-id pub-id-type="pmid">15746175</pub-id></element-citation></ref><ref id="B24-nanomaterials-10-01072"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.-C.</given-names></name><name><surname>Cheng</surname><given-names>H.-F.</given-names></name><name><surname>Yang</surname><given-names>Y.-C.</given-names></name><name><surname>Yeh</surname><given-names>M.-K.</given-names></name></person-group><article-title>Nanotechnologies applied in biomedical vaccines</article-title><source>Micro Nanotechn. Biotech.</source><year>2016</year><pub-id pub-id-type="doi">10.5772/63453d</pub-id></element-citation></ref><ref id="B25-nanomaterials-10-01072"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kingsley</surname><given-names>J.D.</given-names></name><name><surname>Dou</surname><given-names>H.</given-names></name><name><surname>Morehead</surname><given-names>J.</given-names></name><name><surname>Rabinow</surname><given-names>B.</given-names></name><name><surname>Gendelman</surname><given-names>H.E.</given-names></name><name><surname>Destache</surname><given-names>C.J.</given-names></name></person-group><article-title>Nanotechnology: A focus on nanoparticles as a drug delivery system</article-title><source>J. Neuroimmune Pharmacol.</source><year>2006</year><volume>1</volume><fpage>340</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1007/s11481-006-9032-4</pub-id><?supplied-pmid 18040810?><pub-id pub-id-type="pmid">18040810</pub-id></element-citation></ref><ref id="B26-nanomaterials-10-01072"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poeschla</surname><given-names>E.M.</given-names></name></person-group><article-title>Integrase, LEDGF/p75 and HIV replication</article-title><source>Cell. Mol. Life Sci.</source><year>2008</year><volume>65</volume><fpage>1403</fpage><lpage>1424</lpage><pub-id pub-id-type="doi">10.1007/s00018-008-7540-5</pub-id><pub-id pub-id-type="pmid">18264802</pub-id></element-citation></ref><ref id="B27-nanomaterials-10-01072"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adesina</surname><given-names>S.K.</given-names></name><name><surname>Akala</surname><given-names>E.O.</given-names></name></person-group><article-title>Nanotechnology approaches for the delivery of exogenous siRNA for HIV therapy</article-title><source>Mol. Pharm.</source><year>2015</year><volume>12</volume><fpage>4175</fpage><lpage>4187</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.5b00335</pub-id><?supplied-pmid 26524196?><pub-id pub-id-type="pmid">26524196</pub-id></element-citation></ref><ref id="B28-nanomaterials-10-01072"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>L.</given-names></name><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Hu</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name></person-group><article-title>Target delivery of small interfering RNAs with vitamin E-coupled nanoparticles for treating hepatitis C</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>24867</fpage><pub-id pub-id-type="doi">10.1038/srep24867</pub-id><?supplied-pmid 27113197?><pub-id pub-id-type="pmid">27113197</pub-id></element-citation></ref><ref id="B29-nanomaterials-10-01072"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.X.</given-names></name><name><surname>Li</surname><given-names>C.M.</given-names></name><name><surname>Huang</surname><given-names>C.Z.</given-names></name></person-group><article-title>Curcumin modified silver nanoparticles for highly efficient inhibition of respiratory syncytial virus infection</article-title><source>Nanoscale</source><year>2016</year><volume>8</volume><fpage>3040</fpage><lpage>3048</lpage><pub-id pub-id-type="doi">10.1039/C5NR07918G</pub-id><pub-id pub-id-type="pmid">26781043</pub-id></element-citation></ref><ref id="B30-nanomaterials-10-01072"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Guo</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Xia</surname><given-names>H.</given-names></name><name><surname>Zhu</surname><given-names>B.</given-names></name></person-group><article-title>Reversal of H1N1 influenza virus-induced apoptosis by silver nanoparticles functionalized with amantadine</article-title><source>RSC Adv.</source><year>2016</year><volume>6</volume><fpage>89679</fpage><lpage>89686</lpage><pub-id pub-id-type="doi">10.1039/C6RA18493F</pub-id></element-citation></ref><ref id="B31-nanomaterials-10-01072"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>M.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>T.</given-names></name><name><surname>Zhu</surname><given-names>B.</given-names></name></person-group><article-title>Inhibition of H1N1 influenza virus-induced apoptosis by functionalized selenium nanoparticles with amantadine through ROS-mediated AKT signaling pathways</article-title><source>Int. J. Nanomed.</source><year>2018</year><volume>13</volume><fpage>2005</fpage><pub-id pub-id-type="doi">10.2147/IJN.S155994</pub-id></element-citation></ref><ref id="B32-nanomaterials-10-01072"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>M.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Zhu</surname><given-names>B.</given-names></name></person-group><article-title>Inhibitory activity of selenium nanoparticles functionalized with oseltamivir on H1N1 influenza virus</article-title><source>Int. J. Nanomed.</source><year>2017</year><volume>12</volume><fpage>5733</fpage><pub-id pub-id-type="doi">10.2147/IJN.S140939</pub-id></element-citation></ref><ref id="B33-nanomaterials-10-01072"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>C.-M.J.</given-names></name><name><surname>Chen</surname><given-names>Y.-T.</given-names></name><name><surname>Fang</surname><given-names>Z.-S.</given-names></name><name><surname>Chang</surname><given-names>W.-S.</given-names></name><name><surname>Chen</surname><given-names>H.-W.</given-names></name></person-group><article-title>Antiviral efficacy of nanoparticulate vacuolar ATPase inhibitors against influenza virus infection</article-title><source>Int. J. Nanomed.</source><year>2018</year><volume>13</volume><fpage>8579</fpage><pub-id pub-id-type="doi">10.2147/IJN.S185806</pub-id></element-citation></ref><ref id="B34-nanomaterials-10-01072"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Shah</surname><given-names>S.J.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Agrahari</surname><given-names>V.</given-names></name><name><surname>Pal</surname><given-names>D.</given-names></name><name><surname>Mitra</surname><given-names>A.K.</given-names></name></person-group><article-title>Nanoparticle-based topical ophthalmic formulation for sustained release of stereoisomeric dipeptide prodrugs of ganciclovir</article-title><source>Drug Deliv.</source><year>2016</year><volume>23</volume><fpage>2399</fpage><lpage>2409</lpage><pub-id pub-id-type="doi">10.3109/10717544.2014.996833</pub-id><?supplied-pmid 25564964?><pub-id pub-id-type="pmid">25564964</pub-id></element-citation></ref><ref id="B35-nanomaterials-10-01072"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadavalli</surname><given-names>T.</given-names></name><name><surname>Ames</surname><given-names>J.</given-names></name><name><surname>Agelidis</surname><given-names>A.</given-names></name><name><surname>Suryawanshi</surname><given-names>R.</given-names></name><name><surname>Jaishankar</surname><given-names>D.</given-names></name><name><surname>Hopkins</surname><given-names>J.</given-names></name><name><surname>Thakkar</surname><given-names>N.</given-names></name><name><surname>Koujah</surname><given-names>L.</given-names></name><name><surname>Shukla</surname><given-names>D.</given-names></name></person-group><article-title>Drug-encapsulated carbon (DECON): A novel platform for enhanced drug delivery</article-title><source>Sci. Adv.</source><year>2019</year><volume>5</volume><fpage>eaax0780</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aax0780</pub-id><?supplied-pmid 31453334?><pub-id pub-id-type="pmid">31453334</pub-id></element-citation></ref><ref id="B36-nanomaterials-10-01072"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;zt&#x000fc;rk</surname><given-names>A.A.</given-names></name><name><surname>K&#x00131;r&#x00131;ml&#x00131;o&#x0011f;lu</surname><given-names>G.Y.</given-names></name></person-group><article-title>Preparation and in vitro of characterization lamivudine loaded nanoparticles prepared by acid or ester terminated PLGA for effective oral antiretroviral therapy</article-title><source>J. Res. Pharm.</source><year>2019</year><volume>23</volume><fpage>897</fpage><lpage>913</lpage></element-citation></ref><ref id="B37-nanomaterials-10-01072"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatesh</surname><given-names>D.N.</given-names></name><name><surname>Baskaran</surname><given-names>M.</given-names></name><name><surname>Karri</surname><given-names>V.V.S.R.</given-names></name><name><surname>Mannemala</surname><given-names>S.S.</given-names></name><name><surname>Radhakrishna</surname><given-names>K.</given-names></name><name><surname>Goti</surname><given-names>S.</given-names></name></person-group><article-title>Fabrication and in vivo evaluation of Nelfinavir loaded PLGA nanoparticles for enhancing oral bioavailability and therapeutic effect</article-title><source>Saudi Pharm. J.</source><year>2015</year><volume>23</volume><fpage>667</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.jsps.2015.02.021</pub-id><?supplied-pmid 26702262?><pub-id pub-id-type="pmid">26702262</pub-id></element-citation></ref><ref id="B38-nanomaterials-10-01072"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>L.K.</given-names></name><name><surname>Amiji</surname><given-names>M.M.</given-names></name></person-group><article-title>Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS</article-title><source>Pharm. Res.</source><year>2006</year><volume>23</volume><fpage>2638</fpage><lpage>2645</lpage><pub-id pub-id-type="doi">10.1007/s11095-006-9101-7</pub-id><?supplied-pmid 16969696?><pub-id pub-id-type="pmid">16969696</pub-id></element-citation></ref><ref id="B39-nanomaterials-10-01072"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Xie</surname><given-names>C.</given-names></name><name><surname>Cai</surname><given-names>S.</given-names></name><name><surname>Wei</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name></person-group><article-title>PLGA-PEG nanoparticles coated with anti-CD45RO and loaded with HDAC plus protease inhibitors activate latent HIV and inhibit viral spread</article-title><source>Nanoscale Res. Lett.</source><year>2015</year><volume>10</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1186/s11671-015-1112-z</pub-id><?supplied-pmid 26489856?><pub-id pub-id-type="pmid">25977644</pub-id></element-citation></ref><ref id="B40-nanomaterials-10-01072"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sankar</surname><given-names>V.</given-names></name><name><surname>Keerthi</surname><given-names>M.L.</given-names></name><name><surname>Parmar</surname><given-names>N.</given-names></name></person-group><article-title>Formation and In-vitro Evaluation of Zidovudine-Lamivudine Nanoparticles</article-title><source>Ind. J. Pharma. Educ. Res.</source><year>2012</year><volume>46</volume><fpage>192</fpage><lpage>196</lpage></element-citation></ref><ref id="B41-nanomaterials-10-01072"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiandra</surname><given-names>L.</given-names></name><name><surname>Colombo</surname><given-names>M.</given-names></name><name><surname>Mazzucchelli</surname><given-names>S.</given-names></name><name><surname>Truffi</surname><given-names>M.</given-names></name><name><surname>Santini</surname><given-names>B.</given-names></name><name><surname>Allevi</surname><given-names>R.</given-names></name><name><surname>Nebuloni</surname><given-names>M.</given-names></name><name><surname>Capetti</surname><given-names>A.</given-names></name><name><surname>Rizzardini</surname><given-names>G.</given-names></name><name><surname>Prosperi</surname><given-names>D.</given-names></name></person-group><article-title>Nanoformulation of antiretroviral drugs enhances their penetration across the blood brain barrier in mice</article-title><source>Nanomed. Nanotechnol. Biol. Med.</source><year>2015</year><volume>11</volume><fpage>1387</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2015.03.009</pub-id></element-citation></ref><ref id="B42-nanomaterials-10-01072"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donalisio</surname><given-names>M.</given-names></name><name><surname>Leone</surname><given-names>F.</given-names></name><name><surname>Civra</surname><given-names>A.</given-names></name><name><surname>Spagnolo</surname><given-names>R.</given-names></name><name><surname>Ozer</surname><given-names>O.</given-names></name><name><surname>Lembo</surname><given-names>D.</given-names></name><name><surname>Cavalli</surname><given-names>R.</given-names></name></person-group><article-title>Acyclovir-loaded chitosan nanospheres from nano-emulsion templating for the topical treatment of herpesviruses infections</article-title><source>Pharmaceutics</source><year>2018</year><volume>10</volume><elocation-id>46</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics10020046</pub-id></element-citation></ref><ref id="B43-nanomaterials-10-01072"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauster</surname><given-names>D.</given-names></name><name><surname>Glanz</surname><given-names>M.</given-names></name><name><surname>Bardua</surname><given-names>M.</given-names></name><name><surname>Ludwig</surname><given-names>K.</given-names></name><name><surname>Hellmund</surname><given-names>M.</given-names></name><name><surname>Hoffmann</surname><given-names>U.</given-names></name><name><surname>Hamann</surname><given-names>A.</given-names></name><name><surname>B&#x000f6;ttcher</surname><given-names>C.</given-names></name><name><surname>Haag</surname><given-names>R.</given-names></name><name><surname>Hackenberger</surname><given-names>C.P.R.</given-names></name></person-group><article-title>Multivalent Peptide&#x02013;Nanoparticle Conjugates for Influenza-Virus Inhibition</article-title><source>Angew. Chem. Int. Ed.</source><year>2017</year><volume>56</volume><fpage>5931</fpage><lpage>5936</lpage><pub-id pub-id-type="doi">10.1002/anie.201702005</pub-id></element-citation></ref><ref id="B44-nanomaterials-10-01072"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeling</surname><given-names>J.P.</given-names></name><name><surname>Koehn</surname><given-names>J.</given-names></name><name><surname>Shu</surname><given-names>C.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Ho</surname><given-names>R.J.Y.</given-names></name></person-group><article-title>Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates</article-title><source>AIDS Res. Hum. Retrovir.</source><year>2015</year><volume>31</volume><fpage>107</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1089/aid.2014.0210</pub-id><?supplied-pmid 25402233?><pub-id pub-id-type="pmid">25402233</pub-id></element-citation></ref><ref id="B45-nanomaterials-10-01072"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>J.</given-names></name><name><surname>Freeling</surname><given-names>J.P.</given-names></name><name><surname>Koehn</surname><given-names>J.</given-names></name><name><surname>Shu</surname><given-names>C.</given-names></name><name><surname>Ho</surname><given-names>R.J.Y.</given-names></name></person-group><article-title>Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles</article-title><source>J. Pharm. Sci.</source><year>2014</year><volume>103</volume><fpage>2520</fpage><lpage>2529</lpage><pub-id pub-id-type="doi">10.1002/jps.24046</pub-id><pub-id pub-id-type="pmid">24948204</pub-id></element-citation></ref><ref id="B46-nanomaterials-10-01072"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raskin</surname><given-names>M.M.</given-names></name><name><surname>Schlachet</surname><given-names>I.</given-names></name><name><surname>Sosnik</surname><given-names>A.</given-names></name></person-group><article-title>Mucoadhesive nanogels by ionotropic crosslinking of chitosan-g-oligo (NiPAam) polymeric micelles as novel drug nanocarriers</article-title><source>Nanomedicine</source><year>2016</year><volume>11</volume><fpage>217</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.2217/nnm.15.191</pub-id><?supplied-pmid 26786232?><pub-id pub-id-type="pmid">26786232</pub-id></element-citation></ref><ref id="B47-nanomaterials-10-01072"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>S.R.</given-names></name><name><surname>Nagy</surname><given-names>E.</given-names></name><name><surname>Neethirajan</surname><given-names>S.</given-names></name></person-group><article-title>Self-assembled star-shaped chiroplasmonic gold nanoparticles for ultrasensitive chiro-immunosensor of viruses</article-title><source>RSC Adv.</source><year>2017</year><volume>7</volume><fpage>40849</fpage><lpage>40857</lpage><pub-id pub-id-type="doi">10.1039/C7RA07175B</pub-id></element-citation></ref><ref id="B48-nanomaterials-10-01072"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.-N.</given-names></name><name><surname>Hsueh</surname><given-names>Y.-H.</given-names></name><name><surname>Hsieh</surname><given-names>C.-T.</given-names></name><name><surname>Tzou</surname><given-names>D.-Y.</given-names></name><name><surname>Chang</surname><given-names>P.-L.</given-names></name></person-group><article-title>Antiviral activity of graphene-silver nanocomposites against non-enveloped and enveloped viruses</article-title><source>Int. J. Env. Res. Public Health</source><year>2016</year><volume>13</volume><elocation-id>430</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph13040430</pub-id><pub-id pub-id-type="pmid">27104546</pub-id></element-citation></ref><ref id="B49-nanomaterials-10-01072"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Layqah</surname><given-names>L.A.</given-names></name><name><surname>Eissa</surname><given-names>S.</given-names></name></person-group><article-title>An electrochemical immunosensor for the corona virus associated with the Middle East respiratory syndrome using an array of gold nanoparticle-modified carbon electrodes</article-title><source>Mikrochim. Acta</source><year>2019</year><volume>186</volume><fpage>224</fpage><pub-id pub-id-type="doi">10.1007/s00604-019-3345-5</pub-id><pub-id pub-id-type="pmid">30847572</pub-id></element-citation></ref><ref id="B50-nanomaterials-10-01072"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekimukai</surname><given-names>H.</given-names></name><name><surname>Iwata-Yoshikawa</surname><given-names>N.</given-names></name><name><surname>Fukushi</surname><given-names>S.</given-names></name><name><surname>Tani</surname><given-names>H.</given-names></name><name><surname>Kataoka</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Hasegawa</surname><given-names>H.</given-names></name><name><surname>Niikura</surname><given-names>K.</given-names></name><name><surname>Arai</surname><given-names>K.</given-names></name><name><surname>Nagata</surname><given-names>N.</given-names></name></person-group><article-title>Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs</article-title><source>Microbiol. Immunol.</source><year>2020</year><volume>64</volume><fpage>33</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1111/1348-0421.12754</pub-id><pub-id pub-id-type="pmid">31692019</pub-id></element-citation></ref><ref id="B51-nanomaterials-10-01072"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ting</surname><given-names>D.</given-names></name><name><surname>Dong</surname><given-names>N.</given-names></name><name><surname>Fang</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Bi</surname><given-names>J.</given-names></name><name><surname>Xiao</surname><given-names>S.</given-names></name><name><surname>Han</surname><given-names>H.</given-names></name></person-group><article-title>Multisite Inhibitors for Enteric Coronavirus: Antiviral Cationic Carbon Dots Based on Curcumin</article-title><source>ACS Appl. Nano Mater.</source><year>2018</year><volume>1</volume><fpage>5451</fpage><lpage>5459</lpage><pub-id pub-id-type="doi">10.1021/acsanm.8b00779</pub-id></element-citation></ref><ref id="B52-nanomaterials-10-01072"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>T.</given-names></name><name><surname>Liang</surname><given-names>J.</given-names></name><name><surname>Dong</surname><given-names>N.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Fang</surname><given-names>L.</given-names></name><name><surname>Xiao</surname><given-names>S.</given-names></name><name><surname>Han</surname><given-names>H.</given-names></name></person-group><article-title>Glutathione-Capped Ag2S Nanoclusters Inhibit Coronavirus Proliferation through Blockage of Viral RNA Synthesis and Budding</article-title><source>ACS Appl. Mater. Interfaces</source><year>2018</year><volume>10</volume><fpage>4369</fpage><lpage>4378</lpage><pub-id pub-id-type="doi">10.1021/acsami.7b13811</pub-id><pub-id pub-id-type="pmid">29337529</pub-id></element-citation></ref><ref id="B53-nanomaterials-10-01072"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>S.R.</given-names></name><name><surname>Kang</surname><given-names>S.W.</given-names></name><name><surname>Oh</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Neethirajan</surname><given-names>S.</given-names></name></person-group><article-title>Chiral zirconium quantum dots: A new class of nanocrystals for optical detection of coronavirus</article-title><source>Heliyon</source><year>2018</year><volume>4</volume><fpage>e00766</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2018.e00766</pub-id><pub-id pub-id-type="pmid">30186985</pub-id></element-citation></ref><ref id="B54-nanomaterials-10-01072"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mo</surname><given-names>Y.</given-names></name><name><surname>Fisher</surname><given-names>D.</given-names></name></person-group><article-title>Review of Treatment Modalities Of Middle Repsiratorey Syndroms</article-title><source>J. Antimicrob. Chemother.</source><year>2016</year><volume>71</volume><fpage>3340</fpage><lpage>3350</lpage><pub-id pub-id-type="doi">10.1093/jac/dkw338</pub-id><?supplied-pmid 27585965?><pub-id pub-id-type="pmid">27585965</pub-id></element-citation></ref><ref id="B55-nanomaterials-10-01072"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uyeki</surname><given-names>T.M.</given-names></name><name><surname>Erlandson</surname><given-names>K.J.</given-names></name><name><surname>Korch</surname><given-names>G.</given-names></name><name><surname>O&#x02019;Hara</surname><given-names>M.</given-names></name><name><surname>Wathen</surname><given-names>M.</given-names></name><name><surname>Hu-Primmer</surname><given-names>J.</given-names></name><name><surname>Hojvat</surname><given-names>S.</given-names></name><name><surname>Stemmy</surname><given-names>E.J.</given-names></name><name><surname>Donabedian</surname><given-names>A.</given-names></name></person-group><article-title>Evelopment of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus</article-title><source>Emerg. Infect. Dis.</source><year>2016</year><volume>22</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.3201/eid2207.160022</pub-id><?supplied-pmid 27191188?><pub-id pub-id-type="pmid">26694983</pub-id></element-citation></ref><ref id="B56-nanomaterials-10-01072"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Chan</surname><given-names>J.F.W.</given-names></name><name><surname>Azhar</surname><given-names>E.I.</given-names></name><name><surname>Hui</surname><given-names>D.S.C.</given-names></name><name><surname>Yuen</surname><given-names>K.-Y.</given-names></name></person-group><article-title>Coronavirus-Drug Discovery and Therapeutic Options</article-title><source>Nat. Rev</source><year>2016</year><volume>15</volume><fpage>327</fpage><lpage>347</lpage></element-citation></ref><ref id="B57-nanomaterials-10-01072"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00141;oczechin</surname><given-names>A.</given-names></name><name><surname>S&#x000e9;ron</surname><given-names>K.</given-names></name><name><surname>Barras</surname><given-names>A.</given-names></name><name><surname>Giovanelli</surname><given-names>E.</given-names></name><name><surname>Belouzard</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>Y.T.</given-names></name><name><surname>Metzler-Nolte</surname><given-names>N.</given-names></name><name><surname>Boukherroub</surname><given-names>R.</given-names></name><name><surname>Dubuisson</surname><given-names>J.</given-names></name><name><surname>Szunerits</surname><given-names>S.</given-names></name></person-group><article-title>Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus</article-title><source>ACS Appl. Mater. Interfaces</source><year>2019</year><volume>11</volume><fpage>42964</fpage><lpage>42974</lpage><pub-id pub-id-type="doi">10.1021/acsami.9b15032</pub-id><?supplied-pmid 31633330?><pub-id pub-id-type="pmid">31633330</pub-id></element-citation></ref><ref id="B58-nanomaterials-10-01072"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>ERS-Cov Spike Protein: A Key Target for Antivirals</article-title><source>Exp. Opin. Ther. Targets</source><year>2017</year><volume>21</volume><fpage>131</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1080/14728222.2017.1271415</pub-id><?supplied-pmid 27936982?><pub-id pub-id-type="pmid">27936982</pub-id></element-citation></ref><ref id="B59-nanomaterials-10-01072"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Chan</surname><given-names>K.-H.</given-names></name><name><surname>Qin</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Chan</surname><given-names>J.F.W.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Sructures-Based Discovery Of Middle East Repiratory Syndrome Coronavirus Fusion Inhibitor</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>1</fpage><lpage>15</lpage></element-citation></ref><ref id="B60-nanomaterials-10-01072"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szunerits</surname><given-names>S.</given-names></name><name><surname>Barras</surname><given-names>A.</given-names></name><name><surname>Khanal</surname><given-names>M.</given-names></name><name><surname>Pagneux</surname><given-names>Q.</given-names></name><name><surname>Boukherroub</surname><given-names>R.</given-names></name></person-group><article-title>Nanostructures for the Inhibition of Viral Infections</article-title><source>Molecules</source><year>2015</year><volume>20</volume><fpage>14051</fpage><lpage>14081</lpage><pub-id pub-id-type="doi">10.3390/molecules200814051</pub-id><pub-id pub-id-type="pmid">26247927</pub-id></element-citation></ref><ref id="B61-nanomaterials-10-01072"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Meng</surname><given-names>X.</given-names></name><name><surname>An</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Shan</surname><given-names>X.</given-names></name><name><surname>Ge</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Novel Gold Nanorod-Based HR1 Peptide Inhibitor for Middle East Respiratory Syndrome Coronavirus</article-title><source>ACS Appl. Mater. Interfaces</source><year>2019</year><volume>11</volume><fpage>19799</fpage><lpage>19807</lpage><pub-id pub-id-type="doi">10.1021/acsami.9b04240</pub-id><pub-id pub-id-type="pmid">31099550</pub-id></element-citation></ref><ref id="B62-nanomaterials-10-01072"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Tong</surname><given-names>T.</given-names></name><name><surname>Fang</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>J.</given-names></name><name><surname>Xiao</surname><given-names>S.</given-names></name></person-group><article-title>High antiviral activity of mercaptoethane sulfonate functionalized Te/BSA nanostars against arterivirus and coronavirus</article-title><source>RSC Adv.</source><year>2020</year><volume>10</volume><fpage>14161</fpage><lpage>14169</lpage><pub-id pub-id-type="doi">10.1039/D0RA01387K</pub-id></element-citation></ref><ref id="B63-nanomaterials-10-01072"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>J.H.</given-names></name><name><surname>Yalow</surname><given-names>R.S.</given-names></name><name><surname>Berson</surname><given-names>S.A.</given-names></name></person-group><article-title>Radioimmunoassay of Australia antigen</article-title><source>VoxSanguinis</source><year>1970</year><volume>19</volume><fpage>217</fpage><lpage>224</lpage></element-citation></ref><ref id="B64-nanomaterials-10-01072"><label>64.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>A.</given-names></name></person-group><source>Diagnostic Virology Protocols</source><person-group person-group-type="editor"><name><surname>John</surname><given-names>R.</given-names></name><name><surname>Stephenson</surname><given-names>A.W.</given-names></name></person-group><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>1999</year><volume>Volume 2</volume><fpage>56</fpage></element-citation></ref><ref id="B65-nanomaterials-10-01072"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zehbe</surname><given-names>I.</given-names></name><name><surname>Hacker</surname><given-names>G.W.</given-names></name><name><surname>Su</surname><given-names>H.</given-names></name><name><surname>Hauser-Kronberger</surname><given-names>C.</given-names></name><name><surname>Hainfeld</surname><given-names>J.F.</given-names></name><name><surname>Tubbs</surname><given-names>R.</given-names></name></person-group><article-title>Sensitive in situ hybridization with catalyzed reporter deposition, streptavidin-Nanogold, and silver acetate autometallography: Detection of single-copy human papillomavirus</article-title><source>Am. J. Pathol.</source><year>1997</year><volume>150</volume><fpage>1553</fpage><?supplied-pmid 9137082?><pub-id pub-id-type="pmid">9137082</pub-id></element-citation></ref><ref id="B66-nanomaterials-10-01072"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>L.-H.</given-names></name><name><surname>Ramstroem</surname><given-names>O.</given-names></name><name><surname>Yan</surname><given-names>M.</given-names></name></person-group><article-title>Engineering nanomaterial surfaces for biomedical applications</article-title><source>Exp. Biol. Med.</source><year>2009</year><volume>234</volume><fpage>1128</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.3181/0904-MR-134</pub-id><?supplied-pmid 19596820?><pub-id pub-id-type="pmid">19596820</pub-id></element-citation></ref><ref id="B67-nanomaterials-10-01072"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alivisatos</surname><given-names>P.</given-names></name></person-group><article-title>The use of nanocrystals in biological detection</article-title><source>Nat. Biotechnol.</source><year>2004</year><volume>22</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/nbt927</pub-id><pub-id pub-id-type="pmid">14704706</pub-id></element-citation></ref><ref id="B68-nanomaterials-10-01072"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosi</surname><given-names>N.L.</given-names></name><name><surname>Mirkin</surname><given-names>C.A.</given-names></name></person-group><article-title>Nanostructures in biodiagnostics</article-title><source>Chem. Rev.</source><year>2005</year><volume>105</volume><fpage>1547</fpage><lpage>1562</lpage><pub-id pub-id-type="doi">10.1021/cr030067f</pub-id><?supplied-pmid 15826019?><pub-id pub-id-type="pmid">15826019</pub-id></element-citation></ref><ref id="B69-nanomaterials-10-01072"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draz</surname><given-names>M.S.</given-names></name><name><surname>Shafiee</surname><given-names>H.</given-names></name></person-group><article-title>Applications of gold nanoparticles in virus detection</article-title><source>Theranostics</source><year>2018</year><volume>8</volume><fpage>1985</fpage><pub-id pub-id-type="doi">10.7150/thno.23856</pub-id><?supplied-pmid 29556369?><pub-id pub-id-type="pmid">29556369</pub-id></element-citation></ref><ref id="B70-nanomaterials-10-01072"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>G.</given-names></name><name><surname>Gai</surname><given-names>Z.</given-names></name><name><surname>Tao</surname><given-names>Y.</given-names></name><name><surname>Schmitt</surname><given-names>J.</given-names></name><name><surname>Kullak-Ublick</surname><given-names>G.A.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection</article-title><source>ACS Nano.</source><year>2020</year><pub-id pub-id-type="doi">10.1021/acsnano.0c02439</pub-id></element-citation></ref><ref id="B71-nanomaterials-10-01072"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>G.</given-names></name><name><surname>Lee</surname><given-names>G.</given-names></name><name><surname>Kim</surname><given-names>M.J.</given-names></name><name><surname>Baek</surname><given-names>S.H.</given-names></name><name><surname>Choi</surname><given-names>M.</given-names></name><name><surname>Ku</surname><given-names>K.B.</given-names></name><name><surname>Lee</surname><given-names>C.S.</given-names></name><name><surname>Jun</surname><given-names>S.</given-names></name><name><surname>Park</surname><given-names>D.</given-names></name><name><surname>Kim</surname><given-names>H.G.</given-names></name><etal/></person-group><article-title>Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor</article-title><source>ACS Nano.</source><year>2020</year><pub-id pub-id-type="doi">10.1021/acsnano.0c02823</pub-id></element-citation></ref><ref id="B72-nanomaterials-10-01072"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>S.</given-names></name><name><surname>Jasny</surname><given-names>E.</given-names></name><name><surname>Schmidt</surname><given-names>K.E.</given-names></name><name><surname>Petsch</surname><given-names>B.</given-names></name></person-group><article-title>New vaccine technologies to combat outbreak situations</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>1963</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01963</pub-id><pub-id pub-id-type="pmid">30283434</pub-id></element-citation></ref><ref id="B73-nanomaterials-10-01072"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callaway</surname><given-names>E.</given-names></name></person-group><article-title>The race for coronavirus vaccines: A graphical guide</article-title><source>Nature</source><year>2020</year><volume>580</volume><fpage>576</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1038/d41586-020-01221-y</pub-id><pub-id pub-id-type="pmid">32346146</pub-id></element-citation></ref><ref id="B74-nanomaterials-10-01072"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Rao</surname><given-names>Y.</given-names></name><name><surname>Rao</surname><given-names>X.</given-names></name></person-group><article-title>The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines</article-title><source>NPJ Vaccin.</source><year>2020</year><fpage>5</fpage><pub-id pub-id-type="doi">10.1038/s41541-020-0170-0</pub-id></element-citation></ref><ref id="B75-nanomaterials-10-01072"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amanat</surname><given-names>F.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>SARS-CoV-2 Vaccines: Status Report</article-title><source>Immunity</source><year>2020</year><volume>52</volume><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.03.007</pub-id><pub-id pub-id-type="pmid">32259480</pub-id></element-citation></ref><ref id="B76-nanomaterials-10-01072"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thanh Le</surname><given-names>T.</given-names></name><name><surname>Andreadakis</surname><given-names>Z.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>G&#x000f3;mez Rom&#x000e1;n</surname><given-names>R.</given-names></name><name><surname>Tollefsen</surname><given-names>S.</given-names></name><name><surname>Saville</surname><given-names>M.</given-names></name><name><surname>Mayhew</surname><given-names>S.</given-names></name></person-group><article-title>The COVID-19 vaccine development landscape</article-title><source>Nat. Rev. Drug Discov.</source><year>2020</year><volume>19</volume><fpage>305</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1038/d41573-020-00073-5</pub-id><?supplied-pmid 32273591?><pub-id pub-id-type="pmid">32273591</pub-id></element-citation></ref><ref id="B77-nanomaterials-10-01072"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naiman</surname><given-names>B.M.</given-names></name><name><surname>Alt</surname><given-names>D.</given-names></name><name><surname>Bolin</surname><given-names>C.A.</given-names></name><name><surname>Zuerner</surname><given-names>R.</given-names></name><name><surname>Baldwin</surname><given-names>C.L.</given-names></name></person-group><article-title>Protective killed Leptospira borgpetersenii vaccine induces potent Th1 immunity comprising responses by CD4 and &#x003b3;&#x003b4; T lymphocytes</article-title><source>Infect. Immun.</source><year>2001</year><volume>69</volume><fpage>7550</fpage><lpage>7558</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.12.7550-7558.2001</pub-id><?supplied-pmid 11705932?><pub-id pub-id-type="pmid">11705932</pub-id></element-citation></ref><ref id="B78-nanomaterials-10-01072"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>A.</given-names></name><name><surname>Chowdhury</surname><given-names>M.I.</given-names></name><name><surname>Nazim</surname><given-names>M.</given-names></name><name><surname>Alam</surname><given-names>M.M.</given-names></name><name><surname>Ahmed</surname><given-names>T.</given-names></name><name><surname>Hossain</surname><given-names>M.B.</given-names></name><name><surname>Hore</surname><given-names>S.K.</given-names></name><name><surname>Sultana</surname><given-names>G.N.N.</given-names></name><name><surname>Svennerholm</surname><given-names>A.-M.</given-names></name><name><surname>Qadri</surname><given-names>F.</given-names></name></person-group><article-title>Vaccine specific immune response to an inactivated oral cholera vaccine and EPI vaccines in a high and low arsenic area in Bangladeshi children</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>647</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.11.049</pub-id><?supplied-pmid 23200936?><pub-id pub-id-type="pmid">23200936</pub-id></element-citation></ref><ref id="B79-nanomaterials-10-01072"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scallan</surname><given-names>C.D.</given-names></name><name><surname>Tingley</surname><given-names>D.W.</given-names></name><name><surname>Lindbloom</surname><given-names>J.D.</given-names></name><name><surname>Toomey</surname><given-names>J.S.</given-names></name><name><surname>Tucker</surname><given-names>S.N.</given-names></name></person-group><article-title>An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models</article-title><source>Clin. Vaccine Immunol.</source><year>2013</year><volume>20</volume><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1128/CVI.00552-12</pub-id><pub-id pub-id-type="pmid">23155123</pub-id></element-citation></ref><ref id="B80-nanomaterials-10-01072"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>J.E.</given-names></name><name><surname>Tewari</surname><given-names>K.</given-names></name><name><surname>Lyke</surname><given-names>K.E.</given-names></name><name><surname>Sim</surname><given-names>B.K.L.</given-names></name><name><surname>Billingsley</surname><given-names>P.F.</given-names></name><name><surname>Laurens</surname><given-names>M.B.</given-names></name><name><surname>Gunasekera</surname><given-names>A.</given-names></name><name><surname>Chakravarty</surname><given-names>S.</given-names></name><name><surname>James</surname><given-names>E.R.</given-names></name><name><surname>Sedegah</surname><given-names>M.</given-names></name></person-group><article-title>Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity</article-title><source>Science</source><year>2011</year><volume>334</volume><fpage>475</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1126/science.1211548</pub-id><pub-id pub-id-type="pmid">21903775</pub-id></element-citation></ref><ref id="B81-nanomaterials-10-01072"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norton</surname><given-names>E.B.</given-names></name><name><surname>Lawson</surname><given-names>L.B.</given-names></name><name><surname>Mahdi</surname><given-names>Z.</given-names></name><name><surname>Freytag</surname><given-names>L.C.</given-names></name><name><surname>Clements</surname><given-names>J.D.</given-names></name></person-group><article-title>The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens</article-title><source>Infect. Immun.</source><year>2012</year><volume>80</volume><fpage>2426</fpage><lpage>2435</lpage><pub-id pub-id-type="doi">10.1128/IAI.00181-12</pub-id><pub-id pub-id-type="pmid">22526674</pub-id></element-citation></ref><ref id="B82-nanomaterials-10-01072"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tevi-Benissan</surname><given-names>M.C.</given-names></name><name><surname>Moturi</surname><given-names>E.</given-names></name><name><surname>Anya</surname><given-names>B.-P.M.</given-names></name><name><surname>Aschalew</surname><given-names>T.</given-names></name><name><surname>Dicky</surname><given-names>A.B.</given-names></name><name><surname>Nyembo</surname><given-names>P.A.</given-names></name><name><surname>Mbulu</surname><given-names>L.K.</given-names></name><name><surname>Okeibunor</surname><given-names>J.</given-names></name><name><surname>Mihigo</surname><given-names>R.</given-names></name><name><surname>Zawaira</surname><given-names>F.</given-names></name></person-group><article-title>Contribution of polio eradication initiative to effective new vaccine introduction in Africa, 2010&#x02013;2015</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>5193</fpage><lpage>5198</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.05.063</pub-id><pub-id pub-id-type="pmid">27396517</pub-id></element-citation></ref><ref id="B83-nanomaterials-10-01072"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuismer</surname><given-names>S.L.</given-names></name><name><surname>Althouse</surname><given-names>B.M.</given-names></name><name><surname>May</surname><given-names>R.</given-names></name><name><surname>Bull</surname><given-names>J.J.</given-names></name><name><surname>Stromberg</surname><given-names>S.P.</given-names></name><name><surname>Antia</surname><given-names>R.</given-names></name></person-group><article-title>Eradicating infectious disease using weakly transmissible vaccines</article-title><source>Proc. Biol. Sci.</source><year>2016</year><volume>283</volume><fpage>20161903</fpage><pub-id pub-id-type="doi">10.1098/rspb.2016.1903</pub-id><pub-id pub-id-type="pmid">27798311</pub-id></element-citation></ref><ref id="B84-nanomaterials-10-01072"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staroverov</surname><given-names>S.A.</given-names></name><name><surname>Vidyasheva</surname><given-names>I.V.</given-names></name><name><surname>Gabalov</surname><given-names>K.P.</given-names></name><name><surname>Vasilenko</surname><given-names>O.A.</given-names></name><name><surname>Laskavyi</surname><given-names>V.N.</given-names></name><name><surname>Dykman</surname><given-names>L.A.</given-names></name></person-group><article-title>Immunostimulatory effect of gold nanoparticles conjugated with transmissible gastroenteritis virus</article-title><source>Bull. Exp. Biol. Med.</source><year>2011</year><volume>151</volume><fpage>436</fpage><pub-id pub-id-type="doi">10.1007/s10517-011-1350-8</pub-id><pub-id pub-id-type="pmid">22448360</pub-id></element-citation></ref><ref id="B85-nanomaterials-10-01072"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y.S.</given-names></name><name><surname>Son</surname><given-names>A.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Kwon</surname><given-names>S.B.</given-names></name><name><surname>Kim</surname><given-names>M.H.</given-names></name><name><surname>Kim</surname><given-names>P.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Byun</surname><given-names>Y.H.</given-names></name><name><surname>Sung</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Chaperna-Mediated Assembly of Ferritin-Based Middle East Respiratory Syndrome-Coronavirus Nanoparticles</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>1093</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01093</pub-id><?supplied-pmid 29868035?><pub-id pub-id-type="pmid">29868035</pub-id></element-citation></ref><ref id="B86-nanomaterials-10-01072"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L.C.W.</given-names></name><name><surname>Huang</surname><given-names>C.Y.</given-names></name><name><surname>Yao</surname><given-names>B.Y.</given-names></name><name><surname>Lin</surname><given-names>J.C.</given-names></name><name><surname>Agrawal</surname><given-names>A.</given-names></name><name><surname>Algaissi</surname><given-names>A.</given-names></name><name><surname>Peng</surname><given-names>B.H.</given-names></name><name><surname>Liu</surname><given-names>Y.H.</given-names></name><name><surname>Huang</surname><given-names>P.H.</given-names></name><name><surname>Juang</surname><given-names>R.H.</given-names></name><etal/></person-group><article-title>Viromimetic STING agonist-loaded hollow polymeric nanoparticles for safe and effective vaccination against Middle East respiratory syndrome coronavirus</article-title><source>Adv. Funct. Mater.</source><year>2019</year><volume>29</volume><fpage>1807616</fpage><pub-id pub-id-type="doi">10.1002/adfm.201807616</pub-id><?supplied-pmid 32313544?><pub-id pub-id-type="pmid">32313544</pub-id></element-citation></ref><ref id="B87-nanomaterials-10-01072"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>S.Y.</given-names></name><name><surname>Kang</surname><given-names>K.W.</given-names></name><name><surname>Lee</surname><given-names>E.Y.</given-names></name><name><surname>Seo</surname><given-names>D.W.</given-names></name><name><surname>Kim</surname><given-names>H.L.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Kwon</surname><given-names>T.</given-names></name><name><surname>Park</surname><given-names>H.L.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Heterologous prime&#x02013;boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East Respiratory syndrome coronavirus</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>3468</fpage><lpage>3476</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.04.082</pub-id><?supplied-pmid 29739720?><pub-id pub-id-type="pmid">29739720</pub-id></element-citation></ref><ref id="B88-nanomaterials-10-01072"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ball</surname><given-names>J.M.</given-names></name><name><surname>Graham</surname><given-names>D.Y.</given-names></name><name><surname>Opekun</surname><given-names>A.R.</given-names></name><name><surname>Gilger</surname><given-names>M.A.</given-names></name><name><surname>Guerrero</surname><given-names>R.A.</given-names></name><name><surname>Estes</surname><given-names>M.K.</given-names></name></person-group><article-title>Recombinant Norwalk virus&#x02013;like particles given orally to volunteers: Phase I study</article-title><source>Gastroenterology</source><year>1999</year><volume>117</volume><fpage>40</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(99)70548-2</pub-id><pub-id pub-id-type="pmid">10381908</pub-id></element-citation></ref><ref id="B89-nanomaterials-10-01072"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geldmacher</surname><given-names>A.</given-names></name><name><surname>Skrastina</surname><given-names>D.</given-names></name><name><surname>Borisova</surname><given-names>G.</given-names></name><name><surname>Petrovskis</surname><given-names>I.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>D.H.</given-names></name><name><surname>Pumpens</surname><given-names>P.</given-names></name><name><surname>Ulrich</surname><given-names>R.</given-names></name></person-group><article-title>A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>3973</fpage><lpage>3983</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.02.025</pub-id><pub-id pub-id-type="pmid">15917119</pub-id></element-citation></ref><ref id="B90-nanomaterials-10-01072"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Ji</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Surface-engineered gold nanorods: Promising DNA vaccine adjuvant for HIV-1 treatment</article-title><source>Nano Lett.</source><year>2012</year><volume>12</volume><fpage>2003</fpage><lpage>2012</lpage><pub-id pub-id-type="doi">10.1021/nl300027p</pub-id><pub-id pub-id-type="pmid">22372996</pub-id></element-citation></ref><ref id="B91-nanomaterials-10-01072"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>W.</given-names></name><name><surname>Gill</surname><given-names>H.S.</given-names></name></person-group><article-title>M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>2307</fpage><lpage>2315</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.03.063</pub-id><pub-id pub-id-type="pmid">25842219</pub-id></element-citation></ref><ref id="B92-nanomaterials-10-01072"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.-S.</given-names></name><name><surname>Hung</surname><given-names>Y.-C.</given-names></name><name><surname>Lin</surname><given-names>W.-H.</given-names></name><name><surname>Huang</surname><given-names>G.S.</given-names></name></person-group><article-title>Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide</article-title><source>Nanotechnology</source><year>2010</year><volume>21</volume><fpage>195101</fpage><pub-id pub-id-type="doi">10.1088/0957-4484/21/19/195101</pub-id><pub-id pub-id-type="pmid">20400818</pub-id></element-citation></ref><ref id="B93-nanomaterials-10-01072"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>W.</given-names></name><name><surname>Hurst</surname><given-names>B.L.</given-names></name><name><surname>Shakya</surname><given-names>A.K.</given-names></name><name><surname>Uddin</surname><given-names>M.J.</given-names></name><name><surname>Ingrole</surname><given-names>R.S.J.</given-names></name><name><surname>Hernandez-Sanabria</surname><given-names>M.</given-names></name><name><surname>Arya</surname><given-names>R.P.</given-names></name><name><surname>Bimler</surname><given-names>L.</given-names></name><name><surname>Paust</surname><given-names>S.</given-names></name><name><surname>Tarbet</surname><given-names>E.B.</given-names></name></person-group><article-title>Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses</article-title><source>Antivir. Res.</source><year>2017</year><volume>141</volume><fpage>62</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2017.01.021</pub-id><pub-id pub-id-type="pmid">28161578</pub-id></element-citation></ref><ref id="B94-nanomaterials-10-01072"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lugade</surname><given-names>A.A.</given-names></name><name><surname>Bharali</surname><given-names>D.J.</given-names></name><name><surname>Pradhan</surname><given-names>V.</given-names></name><name><surname>Elkin</surname><given-names>G.</given-names></name><name><surname>Mousa</surname><given-names>S.A.</given-names></name><name><surname>Thanavala</surname><given-names>Y.</given-names></name></person-group><article-title>Single low-dose un-adjuvanted HBsAg nanoparticle vaccine elicits robust, durable immunity</article-title><source>Nanomed. Nanotechnol. Biol. Med.</source><year>2013</year><volume>9</volume><fpage>923</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2013.03.008</pub-id></element-citation></ref><ref id="B95-nanomaterials-10-01072"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreiber</surname><given-names>H.A.</given-names></name><name><surname>Prechl</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Zozulya</surname><given-names>A.</given-names></name><name><surname>Fabry</surname><given-names>Z.</given-names></name><name><surname>Denes</surname><given-names>F.</given-names></name><name><surname>Sandor</surname><given-names>M.</given-names></name></person-group><article-title>Using carbon magnetic nanoparticles to target, track, and manipulate dendritic cells</article-title><source>J. Immunol. Method.</source><year>2010</year><volume>356</volume><fpage>47</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2010.02.009</pub-id></element-citation></ref><ref id="B96-nanomaterials-10-01072"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Shi</surname><given-names>X.-M.</given-names></name><name><surname>Gao</surname><given-names>T.-T.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>F.-Q.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Cui</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.-F.</given-names></name></person-group><article-title>Preparation and efficacy of a live newcastle disease virus vaccine encapsulated in chitosan nanoparticles</article-title><source>PLoS ONE</source><year>2012</year><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0053314</pub-id><?supplied-pmid 23285276?><pub-id pub-id-type="pmid">23285276</pub-id></element-citation></ref><ref id="B97-nanomaterials-10-01072"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jesus</surname><given-names>S.</given-names></name><name><surname>Soares</surname><given-names>E.</given-names></name><name><surname>Costa</surname><given-names>J.</given-names></name><name><surname>Borchard</surname><given-names>G.</given-names></name><name><surname>Borges</surname><given-names>O.</given-names></name></person-group><article-title>Immune response elicited by an intranasally delivered HBsAg low-dose adsorbed to poly-&#x003b5;-caprolactone based nanoparticles</article-title><source>Int. J. Pharm.</source><year>2016</year><volume>504</volume><fpage>59</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.03.013</pub-id><?supplied-pmid 26976502?><pub-id pub-id-type="pmid">26976502</pub-id></element-citation></ref><ref id="B98-nanomaterials-10-01072"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>S.</given-names></name><name><surname>Matsuura</surname><given-names>M.</given-names></name><name><surname>Akagi</surname><given-names>T.</given-names></name><name><surname>Akashi</surname><given-names>M.</given-names></name><name><surname>Tanimoto</surname><given-names>T.</given-names></name><name><surname>Ishikawa</surname><given-names>T.</given-names></name><name><surname>Takahashi</surname><given-names>M.</given-names></name><name><surname>Yamanishi</surname><given-names>K.</given-names></name><name><surname>Mori</surname><given-names>Y.</given-names></name></person-group><article-title>Poly (&#x003b3;-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>5896</fpage><lpage>5905</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.07.037</pub-id><?supplied-pmid 19647814?><pub-id pub-id-type="pmid">19647814</pub-id></element-citation></ref><ref id="B99-nanomaterials-10-01072"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bright</surname><given-names>R.A.</given-names></name><name><surname>Carter</surname><given-names>D.M.</given-names></name><name><surname>Daniluk</surname><given-names>S.</given-names></name><name><surname>Toapanta</surname><given-names>F.R.</given-names></name><name><surname>Ahmad</surname><given-names>A.</given-names></name><name><surname>Gavrilov</surname><given-names>V.</given-names></name><name><surname>Massare</surname><given-names>M.</given-names></name><name><surname>Pushko</surname><given-names>P.</given-names></name><name><surname>Mytle</surname><given-names>N.</given-names></name><name><surname>Rowe</surname><given-names>T.</given-names></name></person-group><article-title>Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>3871</fpage><lpage>3878</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.01.106</pub-id><?supplied-pmid 17337102?><pub-id pub-id-type="pmid">17337102</pub-id></element-citation></ref><ref id="B100-nanomaterials-10-01072"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parez</surname><given-names>N.</given-names></name><name><surname>Fourgeux</surname><given-names>C.</given-names></name><name><surname>Mohamed</surname><given-names>A.</given-names></name><name><surname>Dubuquoy</surname><given-names>C.</given-names></name><name><surname>Pillot</surname><given-names>M.</given-names></name><name><surname>Dehee</surname><given-names>A.</given-names></name><name><surname>Charpilienne</surname><given-names>A.</given-names></name><name><surname>Poncet</surname><given-names>D.</given-names></name><name><surname>Schwartz-Cornil</surname><given-names>I.</given-names></name><name><surname>Garbarg-Chenon</surname><given-names>A.</given-names></name></person-group><article-title>Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection</article-title><source>J. Virol.</source><year>2006</year><volume>80</volume><fpage>1752</fpage><lpage>1761</lpage><pub-id pub-id-type="doi">10.1128/JVI.80.4.1752-1761.2006</pub-id><?supplied-pmid 16439532?><pub-id pub-id-type="pmid">16439532</pub-id></element-citation></ref><ref id="B101-nanomaterials-10-01072"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pimentel</surname><given-names>T.A.P.F.</given-names></name><name><surname>Yan</surname><given-names>Z.</given-names></name><name><surname>Jeffers</surname><given-names>S.A.</given-names></name><name><surname>Holmes</surname><given-names>K.V.</given-names></name><name><surname>Hodges</surname><given-names>R.S.</given-names></name><name><surname>Burkhard</surname><given-names>P.</given-names></name></person-group><article-title>Peptide nanoparticles as novel immunogens: Design and analysis of a prototypic severe acute respiratory syndrome vaccine</article-title><source>Chem. Biol. Drug Des.</source><year>2009</year><volume>73</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1111/j.1747-0285.2008.00746.x</pub-id><pub-id pub-id-type="pmid">19152635</pub-id></element-citation></ref><ref id="B102-nanomaterials-10-01072"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borges</surname><given-names>O.</given-names></name><name><surname>Cordeiro-da-Silva</surname><given-names>A.</given-names></name><name><surname>Tavares</surname><given-names>J.</given-names></name><name><surname>Santar&#x000e9;m</surname><given-names>N.</given-names></name><name><surname>de Sousa</surname><given-names>A.</given-names></name><name><surname>Borchard</surname><given-names>G.</given-names></name><name><surname>Junginger</surname><given-names>H.E.</given-names></name></person-group><article-title>Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2008</year><volume>69</volume><fpage>405</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2008.01.019</pub-id><pub-id pub-id-type="pmid">18364251</pub-id></element-citation></ref><ref id="B103-nanomaterials-10-01072"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>C.</given-names></name><name><surname>Rawat</surname><given-names>A.</given-names></name><name><surname>Hope-Weeks</surname><given-names>L.</given-names></name><name><surname>Ahsan</surname><given-names>F.</given-names></name></person-group><article-title>Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine</article-title><source>Mol. Pharm.</source><year>2011</year><volume>8</volume><fpage>405</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1021/mp100255c</pub-id><pub-id pub-id-type="pmid">21189035</pub-id></element-citation></ref><ref id="B104-nanomaterials-10-01072"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghuvanshi</surname><given-names>R.S.</given-names></name><name><surname>Katare</surname><given-names>Y.K.</given-names></name><name><surname>Lalwani</surname><given-names>K.</given-names></name><name><surname>Ali</surname><given-names>M.M.</given-names></name><name><surname>Singh</surname><given-names>O.</given-names></name><name><surname>Panda</surname><given-names>A.K.</given-names></name></person-group><article-title>Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants</article-title><source>Int. J. Pharm.</source><year>2002</year><volume>245</volume><fpage>109</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/S0378-5173(02)00342-3</pub-id><pub-id pub-id-type="pmid">12270248</pub-id></element-citation></ref><ref id="B105-nanomaterials-10-01072"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansoor</surname><given-names>F.</given-names></name><name><surname>Earley</surname><given-names>B.</given-names></name><name><surname>Cassidy</surname><given-names>J.P.</given-names></name><name><surname>Markey</surname><given-names>B.</given-names></name><name><surname>Doherty</surname><given-names>S.</given-names></name><name><surname>Welsh</surname><given-names>M.D.</given-names></name></person-group><article-title>Comparing the immune response to a novel intranasal nanoparticle PLGA vaccine and a commercial BPI3V vaccine in dairy calves</article-title><source>BMC Vet. Res.</source><year>2015</year><volume>11</volume><elocation-id>220</elocation-id><pub-id pub-id-type="doi">10.1186/s12917-015-0481-y</pub-id><?supplied-pmid 26293453?><pub-id pub-id-type="pmid">26293453</pub-id></element-citation></ref><ref id="B106-nanomaterials-10-01072"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGill</surname><given-names>J.L.</given-names></name><name><surname>Kelly</surname><given-names>S.M.</given-names></name><name><surname>Kumar</surname><given-names>P.</given-names></name><name><surname>Speckhart</surname><given-names>S.</given-names></name><name><surname>Haughney</surname><given-names>S.L.</given-names></name><name><surname>Henningson</surname><given-names>J.</given-names></name><name><surname>Narasimhan</surname><given-names>B.</given-names></name><name><surname>Sacco</surname><given-names>R.E.</given-names></name></person-group><article-title>Efficacy of mucosal polyanhydride nanovaccine against respiratory syncytial virus infection in the neonatal calf</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/s41598-018-21292-2</pub-id><?supplied-pmid 29445124?><pub-id pub-id-type="pmid">29311619</pub-id></element-citation></ref><ref id="B107-nanomaterials-10-01072"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francica</surname><given-names>J.R.</given-names></name><name><surname>Lynn</surname><given-names>G.M.</given-names></name><name><surname>Laga</surname><given-names>R.</given-names></name><name><surname>Joyce</surname><given-names>M.G.</given-names></name><name><surname>Ruckwardt</surname><given-names>T.J.</given-names></name><name><surname>Morabito</surname><given-names>K.M.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Chaudhuri</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Sastry</surname><given-names>M.</given-names></name></person-group><article-title>Thermoresponsive polymer nanoparticles co-deliver RSV F trimers with a TLR-7/8 adjuvant</article-title><source>Bioconjugate Chem.</source><year>2016</year><volume>27</volume><fpage>2372</fpage><lpage>2385</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.6b00370</pub-id><?supplied-pmid 27583777?><pub-id pub-id-type="pmid">27583777</pub-id></element-citation></ref><ref id="B108-nanomaterials-10-01072"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynn</surname><given-names>G.M.</given-names></name><name><surname>Laga</surname><given-names>R.</given-names></name><name><surname>Darrah</surname><given-names>P.A.</given-names></name><name><surname>Ishizuka</surname><given-names>A.S.</given-names></name><name><surname>Balaci</surname><given-names>A.J.</given-names></name><name><surname>Dulcey</surname><given-names>A.E.</given-names></name><name><surname>Pechar</surname><given-names>M.</given-names></name><name><surname>Pola</surname><given-names>R.</given-names></name><name><surname>Gerner</surname><given-names>M.Y.</given-names></name><name><surname>Yamamoto</surname><given-names>A.</given-names></name></person-group><article-title>In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity</article-title><source>Nat. Biotechnol.</source><year>2015</year><volume>33</volume><fpage>1201</fpage><pub-id pub-id-type="doi">10.1038/nbt.3371</pub-id><pub-id pub-id-type="pmid">26501954</pub-id></element-citation></ref><ref id="B109-nanomaterials-10-01072"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>W.</given-names></name><name><surname>Roberts</surname><given-names>L.</given-names></name><name><surname>Seryshev</surname><given-names>A.</given-names></name><name><surname>Gubatan</surname><given-names>J.M.</given-names></name><name><surname>Bland</surname><given-names>C.S.</given-names></name><name><surname>Zabriskie</surname><given-names>R.</given-names></name><name><surname>Kulkarni</surname><given-names>S.</given-names></name><name><surname>Soong</surname><given-names>L.</given-names></name><name><surname>Mbawuike</surname><given-names>I.</given-names></name><name><surname>Gilbert</surname><given-names>B.</given-names></name></person-group><article-title>Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic</article-title><source>Mucosal Immunol.</source><year>2011</year><volume>4</volume><fpage>197</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1038/mi.2010.50</pub-id><pub-id pub-id-type="pmid">20736998</pub-id></element-citation></ref><ref id="B110-nanomaterials-10-01072"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Gong</surname><given-names>T.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA</article-title><source>Drug Deliv.</source><year>2016</year><volume>23</volume><fpage>2596</fpage><lpage>2607</lpage><pub-id pub-id-type="doi">10.3109/10717544.2015.1038856</pub-id><pub-id pub-id-type="pmid">26024387</pub-id></element-citation></ref><ref id="B111-nanomaterials-10-01072"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fredriksen</surname><given-names>B.N.</given-names></name><name><surname>Grip</surname><given-names>J.</given-names></name></person-group><article-title>PLGA/PLA micro-and nanoparticle formulations serve as antigen depots and induce elevated humoral responses after immunization of Atlantic salmon (Salmo salar L.)</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>656</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.10.105</pub-id><pub-id pub-id-type="pmid">22100638</pub-id></element-citation></ref><ref id="B112-nanomaterials-10-01072"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Ma</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>K.</given-names></name><name><surname>Jin</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wei</surname><given-names>T.</given-names></name><name><surname>Cao</surname><given-names>W.</given-names></name><name><surname>Zou</surname><given-names>G.</given-names></name><name><surname>Liang</surname><given-names>X.-J.</given-names></name></person-group><article-title>Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment</article-title><source>Biomaterials</source><year>2012</year><volume>33</volume><fpage>1180</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.10.058</pub-id><pub-id pub-id-type="pmid">22056754</pub-id></element-citation></ref><ref id="B113-nanomaterials-10-01072"><label>113.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>McNeil</surname><given-names>S.E.</given-names></name></person-group><article-title>Unique benefits of nanotechnology to drug delivery and diagnostics</article-title><source>Characterization of Nanoparticles Intended for Drug Delivery</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin, Germany</publisher-loc><year>2011</year><fpage>3</fpage><lpage>8</lpage></element-citation></ref><ref id="B114-nanomaterials-10-01072"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiappetta</surname><given-names>D.A.</given-names></name><name><surname>Facorro</surname><given-names>G.</given-names></name><name><surname>de Celis</surname><given-names>E.R.</given-names></name><name><surname>Sosnik</surname><given-names>A.</given-names></name></person-group><article-title>Synergistic encapsulation of the anti-HIV agent efavirenz within mixed poloxamine/poloxamer polymeric micelles</article-title><source>Nanomed. Nanotechnol. Biol. Med.</source><year>2011</year><volume>7</volume><fpage>624</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2011.01.017</pub-id></element-citation></ref><ref id="B115-nanomaterials-10-01072"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos-Martinez</surname><given-names>M.J.</given-names></name><name><surname>Rahme</surname><given-names>K.</given-names></name><name><surname>Corbalan</surname><given-names>J.J.</given-names></name><name><surname>Faulkner</surname><given-names>C.</given-names></name><name><surname>Holmes</surname><given-names>J.D.</given-names></name><name><surname>Tajber</surname><given-names>L.</given-names></name><name><surname>Medina</surname><given-names>C.</given-names></name><name><surname>Radomski</surname><given-names>M.W.</given-names></name></person-group><article-title>Pegylation increases platelet biocompatibility of gold nanoparticles</article-title><source>J. Biomed. Nanotechnol.</source><year>2014</year><volume>10</volume><fpage>1004</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1166/jbn.2014.1813</pub-id><pub-id pub-id-type="pmid">24749395</pub-id></element-citation></ref><ref id="B116-nanomaterials-10-01072"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexis</surname><given-names>F.</given-names></name><name><surname>Pridgen</surname><given-names>E.</given-names></name><name><surname>Molnar</surname><given-names>L.K.</given-names></name><name><surname>Farokhzad</surname><given-names>O.C.</given-names></name></person-group><article-title>Factors affecting the clearance and biodistribution of polymeric nanoparticles</article-title><source>Mol. Pharm.</source><year>2008</year><volume>5</volume><fpage>505</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1021/mp800051m</pub-id><?supplied-pmid 18672949?><pub-id pub-id-type="pmid">18672949</pub-id></element-citation></ref><ref id="B117-nanomaterials-10-01072"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apostolopoulos</surname><given-names>V.</given-names></name><name><surname>Thalhammer</surname><given-names>T.</given-names></name><name><surname>Tzakos</surname><given-names>A.G.</given-names></name><name><surname>Stojanovska</surname><given-names>L.</given-names></name></person-group><article-title>Targeting antigens to dendritic cell receptors for vaccine development</article-title><source>J. Drug Deliv.</source><year>2013</year><volume>2013</volume><pub-id pub-id-type="doi">10.1155/2013/869718</pub-id><?supplied-pmid 24228179?><pub-id pub-id-type="pmid">24228179</pub-id></element-citation></ref><ref id="B118-nanomaterials-10-01072"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghuwanshi</surname><given-names>D.</given-names></name><name><surname>Mishra</surname><given-names>V.</given-names></name><name><surname>Suresh</surname><given-names>M.R.</given-names></name><name><surname>Kaur</surname><given-names>K.</given-names></name></person-group><article-title>A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>7292</fpage><lpage>7299</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.09.036</pub-id><?supplied-pmid 23022399?><pub-id pub-id-type="pmid">23022399</pub-id></element-citation></ref><ref id="B119-nanomaterials-10-01072"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misumi</surname><given-names>S.</given-names></name><name><surname>Masuyama</surname><given-names>M.</given-names></name><name><surname>Takamune</surname><given-names>N.</given-names></name><name><surname>Nakayama</surname><given-names>D.</given-names></name><name><surname>Mitsumata</surname><given-names>R.</given-names></name><name><surname>Matsumoto</surname><given-names>H.</given-names></name><name><surname>Urata</surname><given-names>N.</given-names></name><name><surname>Takahashi</surname><given-names>Y.</given-names></name><name><surname>Muneoka</surname><given-names>A.</given-names></name><name><surname>Sukamoto</surname><given-names>T.</given-names></name></person-group><article-title>Targeted delivery of immunogen to primate m cells with tetragalloyl lysine dendrimer</article-title><source>J. Immunol.</source><year>2009</year><volume>182</volume><fpage>6061</fpage><lpage>6070</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0802928</pub-id><pub-id pub-id-type="pmid">19414757</pub-id></element-citation></ref><ref id="B120-nanomaterials-10-01072"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lepenies</surname><given-names>B.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Sonkaria</surname><given-names>S.</given-names></name></person-group><article-title>Targeting C-type lectin receptors with multivalent carbohydrate ligands</article-title><source>Adv. Drug Deliv. Rev.</source><year>2013</year><volume>65</volume><fpage>1271</fpage><lpage>1281</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2013.05.007</pub-id><pub-id pub-id-type="pmid">23727341</pub-id></element-citation></ref><ref id="B121-nanomaterials-10-01072"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Corbett</surname><given-names>K.S.</given-names></name><name><surname>Goldsmith</surname><given-names>J.A.</given-names></name><name><surname>Hsieh</surname><given-names>C.-L.</given-names></name><name><surname>Abiona</surname><given-names>O.</given-names></name><name><surname>Graham</surname><given-names>B.S.</given-names></name><name><surname>McLellan</surname><given-names>J.S.</given-names></name></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="B122-nanomaterials-10-01072"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>A.C.</given-names></name><name><surname>Park</surname><given-names>Y.J.</given-names></name><name><surname>Tortorici</surname><given-names>M.A.</given-names></name><name><surname>Wall</surname><given-names>A.</given-names></name><name><surname>McGuire</surname><given-names>A.T.</given-names></name><name><surname>Veesler</surname><given-names>D.</given-names></name></person-group><article-title>Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein</article-title><source>Cell</source><year>2020</year><volume>180</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id><pub-id pub-id-type="pmid">31836194</pub-id></element-citation></ref><ref id="B123-nanomaterials-10-01072"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>C.M.</given-names></name><name><surname>Liu</surname><given-names>Y.V.</given-names></name><name><surname>Mu</surname><given-names>H.</given-names></name><name><surname>Taylor</surname><given-names>J.K.</given-names></name><name><surname>Massare</surname><given-names>M.</given-names></name><name><surname>Flyer</surname><given-names>D.C.</given-names></name><name><surname>Smith</surname><given-names>G.E.</given-names></name><name><surname>Frieman</surname><given-names>M.B.</given-names></name></person-group><article-title>Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>3169</fpage><lpage>3174</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.04.016</pub-id><pub-id pub-id-type="pmid">24736006</pub-id></element-citation></ref><ref id="B124-nanomaterials-10-01072"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.V.</given-names></name><name><surname>Massare</surname><given-names>M.J.</given-names></name><name><surname>Barnard</surname><given-names>D.L.</given-names></name><name><surname>Kort</surname><given-names>T.</given-names></name><name><surname>Nathan</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Smith</surname><given-names>G.</given-names></name></person-group><article-title>Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>6606</fpage><lpage>6613</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.111</pub-id><pub-id pub-id-type="pmid">21762752</pub-id></element-citation></ref><ref id="B125-nanomaterials-10-01072"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>C.M.</given-names></name><name><surname>Venkataraman</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>Y.V.</given-names></name><name><surname>Glenn</surname><given-names>G.M.</given-names></name><name><surname>Smith</surname><given-names>G.E.</given-names></name><name><surname>Flyer</surname><given-names>D.C.</given-names></name><name><surname>Frieman</surname><given-names>M.B.</given-names></name></person-group><article-title>MERS-CoV spike nanoparticles protect mice from MERS-CoV infection</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>1586</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.02.012</pub-id><pub-id pub-id-type="pmid">28237499</pub-id></element-citation></ref><ref id="B126-nanomaterials-10-01072"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>T.</given-names></name><name><surname>Takami</surname><given-names>Y.</given-names></name><name><surname>Deo</surname><given-names>V.K.</given-names></name><name><surname>Park</surname><given-names>E.Y.</given-names></name></person-group><article-title>Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells</article-title><source>J. Biotechnol.</source><year>2019</year><volume>306</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2019.10.007</pub-id><?supplied-pmid 31614169?><pub-id pub-id-type="pmid">31614169</pub-id></element-citation></ref><ref id="B127-nanomaterials-10-01072"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Guzman</surname><given-names>D.</given-names></name><name><surname>Le Guen</surname><given-names>P.</given-names></name><name><surname>Villeret</surname><given-names>B.</given-names></name><name><surname>Sola</surname><given-names>N.</given-names></name><name><surname>Le Borgne</surname><given-names>R.</given-names></name><name><surname>Guyard</surname><given-names>A.</given-names></name><name><surname>Kemmel</surname><given-names>A.</given-names></name><name><surname>Crestani</surname><given-names>B.</given-names></name><name><surname>Sallenave</surname><given-names>J.M.</given-names></name><name><surname>Garcia-Verdugo</surname><given-names>I.</given-names></name></person-group><article-title>Silver nanoparticle-adjuvanted vaccine protects against lethal influenza infection through inducing BALT and IgA-mediated mucosal immunity</article-title><source>Biomaterials</source><year>2019</year><volume>217</volume><fpage>119308</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.119308</pub-id><pub-id pub-id-type="pmid">31279103</pub-id></element-citation></ref><ref id="B128-nanomaterials-10-01072"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>S.</given-names></name><name><surname>Shao</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>N.</given-names></name><name><surname>Zuo</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Han</surname><given-names>H.</given-names></name></person-group><article-title>Antiviral Activity of Graphene Oxide: How Sharp Edged Structure and Charge Matter</article-title><source>ACS Appl. Mater. Interfaces</source><year>2015</year><volume>7</volume><fpage>21571</fpage><lpage>21579</lpage><pub-id pub-id-type="doi">10.1021/acsami.5b06876</pub-id><pub-id pub-id-type="pmid">26370151</pub-id></element-citation></ref><ref id="B129-nanomaterials-10-01072"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>T.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Dong</surname><given-names>N.</given-names></name><name><surname>Fang</surname><given-names>L.</given-names></name><name><surname>Xiao</surname><given-names>S.</given-names></name><name><surname>Han</surname><given-names>H.</given-names></name></person-group><article-title>Antiviral Activity of Graphene Oxide&#x02013;Silver Nanocomposites by Preventing Viral Entry and Activation of the Antiviral Innate Immune Response</article-title><source>ACS Appl. Bio Mater.</source><year>2018</year><volume>1</volume><fpage>1286</fpage><lpage>1293</lpage><pub-id pub-id-type="doi">10.1021/acsabm.8b00154</pub-id></element-citation></ref><ref id="B130-nanomaterials-10-01072"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanhai</surname><given-names>W.R.</given-names></name><name><surname>Sakamoto</surname><given-names>J.H.</given-names></name><name><surname>Canady</surname><given-names>R.</given-names></name><name><surname>Ferrari</surname><given-names>M.</given-names></name></person-group><article-title>Seven challenges for nanomedicine</article-title><source>Nat. Nanotechnol.</source><year>2008</year><volume>3</volume><fpage>242</fpage><pub-id pub-id-type="doi">10.1038/nnano.2008.114</pub-id><?supplied-pmid 18654511?><pub-id pub-id-type="pmid">18654511</pub-id></element-citation></ref><ref id="B131-nanomaterials-10-01072"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>R.</given-names></name><name><surname>Gaspar</surname><given-names>R.</given-names></name></person-group><article-title>Nanomedicine (s) under the microscope</article-title><source>Mol. Pharm.</source><year>2011</year><volume>8</volume><fpage>2101</fpage><lpage>2141</lpage><pub-id pub-id-type="doi">10.1021/mp200394t</pub-id><pub-id pub-id-type="pmid">21974749</pub-id></element-citation></ref><ref id="B132-nanomaterials-10-01072"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>M.</given-names></name></person-group><article-title>Cancer nanotechnology: Opportunities and challenges</article-title><source>Nat. Rev. Cancer</source><year>2005</year><volume>5</volume><fpage>161</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1038/nrc1566</pub-id><pub-id pub-id-type="pmid">15738981</pub-id></element-citation></ref><ref id="B133-nanomaterials-10-01072"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Oliveira</surname><given-names>M.P.</given-names></name><name><surname>Garcion</surname><given-names>E.</given-names></name><name><surname>Venisse</surname><given-names>N.</given-names></name><name><surname>Beno&#x000ee;t</surname><given-names>J.-P.</given-names></name><name><surname>Couet</surname><given-names>W.</given-names></name><name><surname>Olivier</surname><given-names>J.-C.</given-names></name></person-group><article-title>Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (&#x02212;/&#x02212;) CF-1 mice</article-title><source>Pharm. Res.</source><year>2005</year><volume>22</volume><fpage>1898</fpage><lpage>1905</lpage><pub-id pub-id-type="doi">10.1007/s11095-005-7147-6</pub-id><pub-id pub-id-type="pmid">16132350</pub-id></element-citation></ref><ref id="B134-nanomaterials-10-01072"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caron</surname><given-names>J.</given-names></name><name><surname>Reddy</surname><given-names>L.H.</given-names></name><name><surname>Lep&#x000ea;tre-Mouelhi</surname><given-names>S.</given-names></name><name><surname>Wack</surname><given-names>S.</given-names></name><name><surname>Clayette</surname><given-names>P.</given-names></name><name><surname>Rogez-Kreuz</surname><given-names>C.</given-names></name><name><surname>Yousfi</surname><given-names>R.</given-names></name><name><surname>Couvreur</surname><given-names>P.</given-names></name><name><surname>Desma&#x000eb;le</surname><given-names>D.</given-names></name></person-group><article-title>Squalenoyl nucleoside monophosphate nanoassemblies: New prodrug strategy for the delivery of nucleotide analogues</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2010</year><volume>20</volume><fpage>2761</fpage><lpage>2764</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2010.03.070</pub-id><pub-id pub-id-type="pmid">20363623</pub-id></element-citation></ref><ref id="B135-nanomaterials-10-01072"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanvicens</surname><given-names>N.</given-names></name><name><surname>Marco</surname><given-names>M.P.</given-names></name></person-group><article-title>Multifunctional nanoparticles&#x02013;properties and prospects for their use in human medicine</article-title><source>Trends Biotechnol.</source><year>2008</year><volume>26</volume><fpage>425</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2008.04.005</pub-id><pub-id pub-id-type="pmid">18514941</pub-id></element-citation></ref><ref id="B136-nanomaterials-10-01072"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagliardi</surname><given-names>M.</given-names></name></person-group><article-title>Biomimetic and bioinspired nanoparticles for targeted drug delivery</article-title><source>Ther. Deliv.</source><year>2017</year><volume>8</volume><fpage>289</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.4155/tde-2017-0013</pub-id><?supplied-pmid 28361608?><pub-id pub-id-type="pmid">28361608</pub-id></element-citation></ref><ref id="B137-nanomaterials-10-01072"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lara</surname><given-names>H.H.</given-names></name><name><surname>Ayala-Nu&#x000f1;ez</surname><given-names>N.V.</given-names></name><name><surname>Ixtepan-Turrent</surname><given-names>L.</given-names></name><name><surname>Rodriguez-Padilla</surname><given-names>C.</given-names></name></person-group><article-title>Mode of antiviral action of silver nanoparticles against HIV-1</article-title><source>J. Nanobiotechn.</source><year>2010</year><volume>8</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/1477-3155-8-1</pub-id><?supplied-pmid 20145735?><pub-id pub-id-type="pmid">20145735</pub-id></element-citation></ref><ref id="B138-nanomaterials-10-01072"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallipeddi</surname><given-names>R.</given-names></name><name><surname>Rohan</surname><given-names>L.C.</given-names></name></person-group><article-title>Progress in antiretroviral drug delivery using nanotechnology</article-title><source>Int. J. Nanomed.</source><year>2010</year><volume>5</volume><fpage>533</fpage></element-citation></ref><ref id="B139-nanomaterials-10-01072"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petros</surname><given-names>R.A.</given-names></name><name><surname>DeSimone</surname><given-names>J.M.</given-names></name></person-group><article-title>Strategies in the design of nanoparticles for therapeutic applications</article-title><source>Nat. Rev. Drug Discov.</source><year>2010</year><volume>9</volume><fpage>615</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1038/nrd2591</pub-id><pub-id pub-id-type="pmid">20616808</pub-id></element-citation></ref><ref id="B140-nanomaterials-10-01072"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurer</surname><given-names>P.</given-names></name><name><surname>Jennings</surname><given-names>G.T.</given-names></name><name><surname>Willers</surname><given-names>J.</given-names></name><name><surname>Rohner</surname><given-names>F.</given-names></name><name><surname>Lindman</surname><given-names>Y.</given-names></name><name><surname>Roubicek</surname><given-names>K.</given-names></name><name><surname>Renner</surname><given-names>W.A.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>P.</given-names></name><name><surname>Bachmann</surname><given-names>M.F.</given-names></name></person-group><article-title>A therapeutic vaccine for nicotine dependence: Preclinical efficacy, and Phase I safety and immunogenicity</article-title><source>Eur. J. Immunol.</source><year>2005</year><volume>35</volume><fpage>2031</fpage><lpage>2040</lpage><pub-id pub-id-type="doi">10.1002/eji.200526285</pub-id><pub-id pub-id-type="pmid">15971275</pub-id></element-citation></ref><ref id="B141-nanomaterials-10-01072"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roldao</surname><given-names>A.</given-names></name><name><surname>Mellado</surname><given-names>M.C.M.</given-names></name><name><surname>Castilho</surname><given-names>L.R.</given-names></name><name><surname>Carrondo</surname><given-names>M.J.T.</given-names></name><name><surname>Alves</surname><given-names>P.M.</given-names></name></person-group><article-title>Virus-like particles in vaccine development</article-title><source>Expert Rev. Vaccin.</source><year>2010</year><volume>9</volume><fpage>1149</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1586/erv.10.115</pub-id></element-citation></ref><ref id="B142-nanomaterials-10-01072"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenwood</surname><given-names>B.</given-names></name></person-group><article-title>The contribution of vaccination to global health: Past, present and future</article-title><source>R. Soc.</source><year>2014</year><volume>369</volume><fpage>20130433</fpage><pub-id pub-id-type="doi">10.1098/rstb.2013.0433</pub-id></element-citation></ref><ref id="B143-nanomaterials-10-01072"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peek</surname><given-names>L.J.</given-names></name><name><surname>Middaugh</surname><given-names>C.R.</given-names></name><name><surname>Berkland</surname><given-names>C.</given-names></name></person-group><article-title>Nanotechnology in vaccine delivery</article-title><source>Adv. Drug Deliv. Rev.</source><year>2008</year><volume>60</volume><fpage>915</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2007.05.017</pub-id><pub-id pub-id-type="pmid">18325628</pub-id></element-citation></ref><ref id="B144-nanomaterials-10-01072"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandedkar</surname><given-names>T.D.</given-names></name></person-group><article-title>Nanovaccines: Recent developments in vaccination</article-title><source>J. Biosci.</source><year>2009</year><volume>34</volume><fpage>995</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1007/s12038-009-0114-3</pub-id><pub-id pub-id-type="pmid">20093753</pub-id></element-citation></ref><ref id="B145-nanomaterials-10-01072"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Seth</surname><given-names>A.</given-names></name><name><surname>Wibowo</surname><given-names>N.</given-names></name><name><surname>Zhao</surname><given-names>C.-X.</given-names></name><name><surname>Mitter</surname><given-names>N.</given-names></name><name><surname>Yu</surname><given-names>C.</given-names></name><name><surname>Middelberg</surname><given-names>A.P.J.</given-names></name></person-group><article-title>Nanoparticle vaccines</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>327</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.11.069</pub-id><pub-id pub-id-type="pmid">24295808</pub-id></element-citation></ref><ref id="B146-nanomaterials-10-01072"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerry</surname><given-names>R.G.</given-names></name><name><surname>Malik</surname><given-names>S.</given-names></name><name><surname>Redda</surname><given-names>Y.T.</given-names></name><name><surname>Sahoo</surname><given-names>S.</given-names></name><name><surname>Patra</surname><given-names>J.K.</given-names></name><name><surname>Majhi</surname><given-names>S.</given-names></name></person-group><article-title>Nano-based approach to combat emerging viral (NIPAH virus) infection</article-title><source>Nanomed. Nanotechnol. Biol. Med.</source><year>2019</year><volume>18</volume><fpage>196</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2019.03.004</pub-id><?supplied-pmid 30904587?><pub-id pub-id-type="pmid">30904587</pub-id></element-citation></ref><ref id="B147-nanomaterials-10-01072"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaligram</surname><given-names>S.</given-names></name><name><surname>Campbell</surname><given-names>A.</given-names></name></person-group><article-title>Toxicity of copper salts is dependent on solubility profile and cell type tested</article-title><source>Toxicol. Vitr.</source><year>2013</year><volume>27</volume><fpage>844</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1016/j.tiv.2012.12.026</pub-id></element-citation></ref><ref id="B148-nanomaterials-10-01072"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>A.-G.</given-names></name><name><surname>Huang</surname><given-names>J.-Q.</given-names></name><name><surname>Huang</surname><given-names>Y.-Q.</given-names></name><name><surname>Wang</surname><given-names>G.-X.</given-names></name></person-group><article-title>Anti-betanodavirus activity of isoprinosine and improved efficacy using carbon nanotubes based drug delivery system</article-title><source>Aquaculture</source><year>2019</year><volume>512</volume><fpage>734377</fpage><pub-id pub-id-type="doi">10.1016/j.aquaculture.2019.734377</pub-id></element-citation></ref><ref id="B149-nanomaterials-10-01072"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>L.</given-names></name><name><surname>Kruger</surname><given-names>H.G.</given-names></name><name><surname>Maguire</surname><given-names>G.E.M.</given-names></name><name><surname>Govender</surname><given-names>T.</given-names></name><name><surname>Parboosing</surname><given-names>R.</given-names></name></person-group><article-title>The role of nanotechnology in the treatment of viral infections</article-title><source>Adv. Infect. Dis.</source><year>2017</year><volume>4</volume><fpage>105</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1177/2049936117713593</pub-id><?supplied-pmid 28748089?><pub-id pub-id-type="pmid">28748089</pub-id></element-citation></ref><ref id="B150-nanomaterials-10-01072"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dormont</surname><given-names>F.</given-names></name><name><surname>Brusini</surname><given-names>R.</given-names></name><name><surname>Cailleau</surname><given-names>C.</given-names></name><name><surname>Reynaud</surname><given-names>F.</given-names></name><name><surname>Peramo</surname><given-names>A.</given-names></name><name><surname>Gendron</surname><given-names>A.</given-names></name><name><surname>Mougin</surname><given-names>J.</given-names></name><name><surname>Gaudin</surname><given-names>F.</given-names></name><name><surname>Varna</surname><given-names>M.</given-names></name><name><surname>Couvreur</surname><given-names>P.</given-names></name></person-group><article-title>Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation</article-title><source>Sci. Adv.</source><year>2020</year><fpage>eaaz5466</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aaz5466</pub-id><pub-id pub-id-type="pmid">32548259</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="nanomaterials-10-01072-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Types of common viral infections, the details are obtained from Ref. [<xref rid="B9-nanomaterials-10-01072" ref-type="bibr">9</xref>].</p></caption><graphic xlink:href="nanomaterials-10-01072-g001"/></fig><fig id="nanomaterials-10-01072-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>SARS-CoV, MERS-CoV, and SARS-CoV-2 classification. Redrawn from [<xref rid="B12-nanomaterials-10-01072" ref-type="bibr">12</xref>], an open access article (CC BY).</p></caption><graphic xlink:href="nanomaterials-10-01072-g002"/></fig><fig id="nanomaterials-10-01072-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Nano-based approaches against viruses, especially coronaviruses (CoVs).</p></caption><graphic xlink:href="nanomaterials-10-01072-g003"/></fig><fig id="nanomaterials-10-01072-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Field-effect transistor (FET) sensor and its related operational process for the diagnosis of COVID-19. Reproduced (adapted) with permission from [<xref rid="B71-nanomaterials-10-01072" ref-type="bibr">71</xref>]. Copyright <sup>&#x000a9; 2020</sup>, American Chemical Society.</p></caption><graphic xlink:href="nanomaterials-10-01072-g004"/></fig><fig id="nanomaterials-10-01072-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>The onset of the clinical vaccine&#x02019;s development against massive outbreaks. Ad4, 5, or 26 vectors (human adenovirus type 4, 5, or 26); ChAd (chimpanzee adenovirus); MVA (modified vaccinia Ankara); VSV (vesicular stomatitis virus); HPIV3 (human parainfluenza virus type 3); MV (measles virus). Redrawn with permission from [<xref rid="B72-nanomaterials-10-01072" ref-type="bibr">72</xref>], an open access article (CC BY).</p></caption><graphic xlink:href="nanomaterials-10-01072-g005"/></fig><fig id="nanomaterials-10-01072-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Eight types of explored vaccines against CoV, based on various viruses or viral parts. Redrawn from [<xref rid="B73-nanomaterials-10-01072" ref-type="bibr">73</xref>]. The details are obtained from WHO COVID-19 Vaccine Landscape and [<xref rid="B74-nanomaterials-10-01072" ref-type="bibr">74</xref>,<xref rid="B75-nanomaterials-10-01072" ref-type="bibr">75</xref>,<xref rid="B76-nanomaterials-10-01072" ref-type="bibr">76</xref>].</p></caption><graphic xlink:href="nanomaterials-10-01072-g006"/></fig><fig id="nanomaterials-10-01072-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Nanotechnologies utilized in nanomedicine vaccines. Ag (antigen); Ab (antibody); APC (antigen presenting cell); IgG (serum immunoglobulin G); AFC (antibody forming cell); ADCC (antibody-dependent cytotoxic cell); Tc (cytotoxic T-cell); GC (granulocyte); Th (helper T-cell); MAC (macrophage); MC (memory cell); NKC (natural killer cell). Reproduced with permission from [<xref rid="B24-nanomaterials-10-01072" ref-type="bibr">24</xref>], (CC BY).</p></caption><graphic xlink:href="nanomaterials-10-01072-g007"/></fig><fig id="nanomaterials-10-01072-f008" orientation="portrait" position="float"><label>Figure 8</label><caption><p>Carbon quantum dots (CQDs) prepared using hydrothermal carbonization and their influence on binding of HCoV-229E virus to cells: (<bold>a</bold>) inhibition of protein S receptor interface, (<bold>b</bold>) inhibition of viral RNA genome replication. Redrawn with permission from [<xref rid="B57-nanomaterials-10-01072" ref-type="bibr">57</xref>]. Copyright <sup>&#x000a9; 2020</sup>, American Chemical Society.</p></caption><graphic xlink:href="nanomaterials-10-01072-g008"/></fig><fig id="nanomaterials-10-01072-f009" orientation="portrait" position="float"><label>Figure 9</label><caption><p>Biosensor design representation: (<bold>A</bold>) zirconium (Zr) NPs and CoV under reducing agent; (<bold>B</bold>) Zr QDs preparation; (<bold>C</bold>) the Ab linked QDs; (<bold>D</bold>) adding Ab-conjugated magneto-plasmonic (MP) NPs; (<bold>E</bold>) the generation of nanostructured MP fluorescent with the target&#x02019;s addition and subsequent separation process (<bold>F</bold>); (<bold>G</bold>) dispersion of the nanohybrid-conjugated part and the following measurement of the optical characteristics (PL: photoluminescence) (<bold>H</bold>). Redrawn with permission from [<xref rid="B53-nanomaterials-10-01072" ref-type="bibr">53</xref>].</p></caption><graphic xlink:href="nanomaterials-10-01072-g009"/></fig><table-wrap id="nanomaterials-10-01072-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">nanomaterials-10-01072-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary of developed nanoparticulate drug delivery systems towards treatment and/or therapy of viral infections.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Nanoplatform</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Properties (Shape/Size/Toxicity)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Refs.</th></tr></thead><tbody><tr><td rowspan="12" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>NPs</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silver (Ag)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monodisperse and uniformly spherical; highly stable Ag@AM (2 nm &#x0003e; 28 days); Ag NPs loaded with AM on their surface less cytotoxic (~90%) than free AgNPs (65%) or AM (56%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amantadine (AM)</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">H1N1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-nanomaterials-10-01072" ref-type="bibr">30</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Selenium (Se)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uniformly spherical Se@AM (70 nm)&#x02014;more stable, superior antiviral effect on kidney cells treated with H1N1 and less cytotoxicity (79.26% viability) than SeNPs (200 nm, 58.8%) and/or free AM (53.23%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-nanomaterials-10-01072" ref-type="bibr">31</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uniformly spherical Se@OTV (100 nm)&#x02014;superior antiviral effect on kidney cells treated with H1N1 and less cytotoxicity (93% viability) than SeNPs (60%) and/or free OTV (53%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oseltamivir (OTV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-nanomaterials-10-01072" ref-type="bibr">32</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-PLGA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uniformly spherical shape; NPs (178 nm &#x00026; 197 nm) loaded with diphyllin and bafilomycin; high biocompatibility and antiviral activity towards the NP drugs than the free drugs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diphyllin &#x00026; Bafilomycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-nanomaterials-10-01072" ref-type="bibr">33</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uniform, spherical/smooth surface NPs (116&#x02212;143 nm); three GCV pro-drugs can be separately loaded on PLGA NPs; non-cytotoxic PLGA NPs (24 h and 48 h contact of three diverse NPs concentrations with HCEC cell)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gangiclovir (GCV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV <sup>a</sup> -1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-nanomaterials-10-01072" ref-type="bibr">34</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPAC</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99% drug loading efficiency; HPAC (diverse concentrations)&#x02014;non-cytotoxic towards human epithelial cells (vaginal, corneal), foreskin fibroblasts, HeLa cells: cell viability &#x0003e;75%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acyclovir (ACV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B35-nanomaterials-10-01072" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polydisperse particles loaded with LAM (221&#x02212;250 nm); slow NPs degradation in simulated intestinal fluid PBS; the molecular interaction between polymer and LAM confirmed by FTIR and DSC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lamivudine (LAM)</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">HIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-nanomaterials-10-01072" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical/smooth surface NFV NPs (~185 nm); almost narrow distribution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Efavirenz (EFV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-nanomaterials-10-01072" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEO-PCL</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical PEO-PCL NPs (~200&#x02212;270 nm)with smooth surface; SQV is encapsulated into NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saquinavir (SQV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-nanomaterials-10-01072" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA-PEG</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical shape (~125 nm) for those loaded with SAHA and NFV; ~119 nm for those loaded with SAHA; ~118 nm for NPs loaded with NFV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suberoylanilide hydroxamic acid (SAHA) and NFV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B39-nanomaterials-10-01072" ref-type="bibr">39</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hybrid NPs (PLGA, PLA, MMA-SPM, and PMMA)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Almost spherical NPs; PLGA NPs (58~224 nm) and MMA-SPM NPs (91&#x02212;823 nm); nontoxic NPs (male mice)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LAM+AZT (Zidovudine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-nanomaterials-10-01072" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PMA coated MNP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uniformly spherical NPs conjugated with ENF (35.2 nm); nontoxic in vivo and in vitro NPs conjugated with ENF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enfuvirtide (ENF)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-nanomaterials-10-01072" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Nanospheres (NS)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitosan (Cs)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical NS (~200 nm diameter) with smooth surface; polydisperse NS; after contact with NS has a satisfactory Vero cell viability; 86% ACV encapsulation efficiency</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-nanomaterials-10-01072" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Dendrimers</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PG <sup>b</sup></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiviral effect in vitro; nontoxic peptide-PG conjugates in vitro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptides</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IAV <sup>c</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-nanomaterials-10-01072" ref-type="bibr">43</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Lipid NPs (LNPs)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DSPC <sup>d</sup> +MPEG+DSPE</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LNPs (52~68 nm); in vivo antiHIV LNPS do not display local reactions, and also animal platelet counts were within normal limits</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LPV <sup>e</sup> +TFV <sup>f</sup> +RTV <sup>g</sup></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">HIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B44-nanomaterials-10-01072" ref-type="bibr">44</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG and phospholipids</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LNPs loaded with drug or drugs (33~68 nm); incorporation efficiency (88~96%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATV <sup>h</sup> +TFV+RTV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-nanomaterials-10-01072" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Micelles</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cs-<italic>g</italic>-oligo(NiPAam)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Copolymers self-assembled in multimicellar aggregates by hydrodynamic (330~436 nm); high mucoadhesion and cytocompatibility properties</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EFV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-nanomaterials-10-01072" ref-type="bibr">46</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Herpes simplex virus; <sup>b</sup> polyglycerol; <sup>c</sup> influenza A virus; <sup>d</sup> 1,2-Distearoyl-sn-glycero-3-phosphocholine; <sup>e</sup> Lopinavir (LPV); <sup>f</sup> Tenofovir; <sup>g</sup> Ritonavir; <sup>h</sup> Atazanavir.</p></fn></table-wrap-foot></table-wrap><table-wrap id="nanomaterials-10-01072-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">nanomaterials-10-01072-t002_Table 2</object-id><label>Table 2</label><caption><p>Engineered nanomaterials to detect and inhibit CoVs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NPs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanistic Aspects</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Purpose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Refs.</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chiral gold NPs-quantum dot (QD) nanocomposites</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CoVs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chiral plasmon&#x02013;exciton systems</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral detection</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-nanomaterials-10-01072" ref-type="bibr">47</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Graphene oxide (GO) sheets</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Feline CoVs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Organism models: fcwf-4 cells, DF-1 cells; association with viral lipid tails leading to aggregation and rupture of the envelop</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral inhibition</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-nanomaterials-10-01072" ref-type="bibr">48</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GO sheets with silver particles</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Feline CoVs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Association with viral lipid tails leading to aggregation with attachment of silver NPs with &#x02013;SH group of protein and rupture of the envelop</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral inhibition</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-nanomaterials-10-01072" ref-type="bibr">48</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carbon electrodes modified with gold NPs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MERS CoVs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant spike protein S1 has been employed as a biomarker; the sensor is based on indirect competition between free virus in the sample and immobilized MERS-CoV protein for a fixed concentration of added antibody to the sample</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral detection </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-nanomaterials-10-01072" ref-type="bibr">49</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gold NP&#x02013;adjuvanted S protein</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoVs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stimulates significant antigen&#x02013;specific IgG response against SARS&#x02013;related CoV infection</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Development of vaccines against severe pneumonia&#x02013;associated CoVs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-nanomaterials-10-01072" ref-type="bibr">50</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cationic carbon dots based on curcumin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CoVs; porcine epidemic diarrhea virus (PEDV)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of the viral proliferation; the structure of surface protein in viruses has been changed, thus prohibiting viral entry; cationic carbon dots based on curcumin can suppress the synthesis of negative-strand RNA and budding of the virus, and the accumulation of reactive oxygen species by virus. Further, it can suppress viral replication by stimulating the formation of interferon-stimulating genes (ISGs) and pro-inflammatory cytokines</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiviral properties </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-nanomaterials-10-01072" ref-type="bibr">51</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glutathione-capped Ag<sub>2</sub>S nanoclusters (NCs)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEDV as a model of CoV</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ag<sub>2</sub>S NCs treatment prohibited the formation of viral negative-strand RNA and viral budding. It positively regulated the production of IFN-stimulating genes (ISGs) and the expression of pro-inflammation cytokines, which may inhibit the virus infection; inhibition of CoV proliferation </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral inhibition </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-nanomaterials-10-01072" ref-type="bibr">52</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chiral zirconium QDs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CoVs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The fluorescence properties of immuno-conjugated QD-magneto-plasmonic NPs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral detection </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B53-nanomaterials-10-01072" ref-type="bibr">53</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="nanomaterials-10-01072-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">nanomaterials-10-01072-t003_Table 3</object-id><label>Table 3</label><caption><p>Some important Au NP-based strategies towards the detection of viruses [<xref rid="B69-nanomaterials-10-01072" ref-type="bibr">69</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Virus</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Target</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Au NP Systems</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Assay</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Detection Limit &#x00026; Detection Range</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Time (min)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shape &#x00026; Size (nm)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biomolecule</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SARS- CoV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NC <sup>a</sup> protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Electrochemical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5 pM, 50&#x02013;2.5 pM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;120</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PP1ab <sup>b</sup> gene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorimetric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60 fmol, ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MERS-CoV</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E protein gene (upE) and open reading frames (ORF) 1a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorimetric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 pmol/&#x003bc;L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">HCV</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCV antigen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Electrical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 pg/&#x003bc;L, 10 ng/&#x003bc;L&#x02212;1 pg/&#x003bc;L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">245</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCV Ab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPA <sup>c</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scanometric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 ng/mL, 3 &#x003bc;g/mL&#x02212;3 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Core gene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 8~15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DLS/Colorimetric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.36 pM, 0.3 &#x003bc;M&#x02212;0.3 pM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Full genome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorimetric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 copies, ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">110</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluorometric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">300 fM, 550&#x02212;15 pM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">184</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">5&#x02032; UTR <sup>d</sup> gene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 10~15</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Electrochemical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~1 pM, 2.0&#x02212;0.01 nM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorimetric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 fmol, 30&#x02212;2 fmol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50</td></tr><tr><td rowspan="14" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">HBV</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-HBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scanometric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 ng/mL, 3 &#x003bc;g/mL&#x02212;3 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C <sup>e</sup> gene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scanometric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 fM, 10<sup>&#x02212;11</sup>&#x02212;10<sup>&#x02212;15</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">S <sup>f</sup> gene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 8~15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorimetric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.36 pM, 0.3 &#x003bc;M&#x02212;0.3 pM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Spherical, 5</td><td align="center" valign="middle" rowspan="1" colspan="1">Avidin</td><td align="center" valign="middle" rowspan="1" colspan="1">Electrochemical</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7 ng/mL, 1.47&#x02212;0.7 ng/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">105</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scanometric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 fM, At 20 fM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">330</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBV DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rod, ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluorometric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 pM, 6.0&#x02212;0.045 nM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~60</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBeAg <sup>g</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rod, L = 46, D = 13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluorometric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.3 ng/mL, Up to 264 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td></tr><tr><td rowspan="7" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">HBsAg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 10, 50, 100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DLS <sup>h</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005 IU/mL, 1&#x02212;0.005 IU/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c2;60</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ab</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Electrochemical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1 ng/mL, 650&#x02212;0.5 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, ~10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.3 pg/mL, 1.0&#x02212;0.01 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87 pg/mL, 1500&#x02212;0.1 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~50</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rod, L = 46, D = 13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluorometric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 ng/mL, Up to 288 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rod, L = 68, D = n30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LSPR <sup>i</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01 IU/mL, 1&#x02212;0.01 IU/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 5.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluorometric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1 pg/mL, 0.1&#x02212;0.0001 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">H1N1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-H1N1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DLS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x002c2;100 TCID50/mL, 1.4 &#x000d7; 10<sup>6</sup>&#x02212;5.5 &#x000d7; 10<sup>3</sup> TCID50/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">NA gene</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Spherical, ND</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DNA</td><td align="center" valign="middle" rowspan="1" colspan="1">SERS <sup>j</sup></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">25 nM, 50&#x02212;25 nM</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ND</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluorometric</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA antigen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluorometric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.9 pg/mL, 800&#x02212;12.5 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M <sup>k</sup> gene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avidin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Electrochemical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">577 pM, 3&#x02212;0.001 pmol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80&#x02013;50</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">H5N1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA <sup>l</sup> gene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scanometric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 fM &#x00026;103 TCID50, ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">150</td></tr><tr><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">HA <sup>m</sup> gene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorimetric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40&#x02013;0.1 ng, 100&#x02212;0.1 ng</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Electrochemical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4 pM, 1.0 nM&#x02212;5.0 pM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daunorubicin</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Scanometric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 pM, 10 pM&#x02212;100 nM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 1.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 pM, 10 pM&#x02212;100 nM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 fM &#x00026; 103 TCID50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">150</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Particles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pentabody</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorimetric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 ng/mL, 10<sup>&#x02212;1</sup>&#x02212;10<sup>&#x02212;4</sup> &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluorometric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.09 ng/mL, 12&#x02212;0.27 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV-2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-HSV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorimetric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND, ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">HIV</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">P24 Antigen <sup>n</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avidin/DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scanometric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1 pg/mL, 500&#x02212;0.1 pg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~360</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avidin/DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DLS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2 pM, 31.4 pM&#x02212;1.6 fM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;170</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ab/DNA</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IPCR<sup>o</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1 pg/mL, 1000&#x02212;0.1 pg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;85</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ab/DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 pg/mL, 10,000&#x02212;1 pg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;125</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Pol</italic><sup>p</sup> gene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DLS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 fM, 10 nM&#x02212;1 fM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Electrochemical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.34 fM, 1.0 &#x000b5;M&#x02212;0.1 pM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Nucleocapsid; <sup>b</sup> ployprotein1ab; <sup>c</sup> staphylococcal protein A; <sup>d</sup> five-prime untranslated region; <sup>e</sup> core; <sup>f</sup> surface; <sup>g</sup> hepatitis B antigen; <sup>h</sup> dynamic light scattering; <sup>i</sup> localized surface plasmon resonance; <sup>j</sup> surface enhanced Raman scattering; <sup>k</sup> matrix; <sup>l</sup> neuraminidase; <sup>m</sup> hemagglutinin; <sup>n</sup> P24 capsid protein antigen; <sup>o</sup> immuno-PCR; <sup>p</sup> polymerase gene; gene.</p></fn></table-wrap-foot></table-wrap><table-wrap id="nanomaterials-10-01072-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">nanomaterials-10-01072-t004_Table 4</object-id><label>Table 4</label><caption><p>Some important examples of NP-based vaccine candidates against CoVs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type of CoVs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NPs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Findings</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Refs.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Swine TGEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gold NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gold NPs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acceleration of the peritoneal macrophages respiratory activity and plasma IFN-&#x003b3; level</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B84-nanomaterials-10-01072" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gold NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gold NPs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stimulation of IgG response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-nanomaterials-10-01072" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MERS-CoV (RBD antigen)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ferritin-based NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stimulation of CD<sup>4+</sup> T-cells and IFN-&#x003b3; TNF-&#x003b1; responses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B85-nanomaterials-10-01072" ref-type="bibr">85</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MERS-CoV (RBD antigen)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hollow polymeric NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STING agonist (cdGMP)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stimulation of remarkable levels of humoral responses and IgG2a antibodies, with no stimulation in lung eosinophilic immunopathology</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B86-nanomaterials-10-01072" ref-type="bibr">86</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MERS-CoV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spike protein NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aluminum</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stimulation of significant titers of neutralizing antibody and Th2 immune response, with no stimulation of Th1 immune response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B87-nanomaterials-10-01072" ref-type="bibr">87</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="nanomaterials-10-01072-t005" orientation="portrait" position="float"><object-id pub-id-type="pii">nanomaterials-10-01072-t005_Table 5</object-id><label>Table 5</label><caption><p>Summary of diverse types of nanocarrier/NP-based vaccine delivery systems against viral infections.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nanocarriers Delivery System</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen/Adjuvant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Route of Administration</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Refs.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gold NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral plasmid DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV/AIDS pandemic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intradermal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B90-nanomaterials-10-01072" ref-type="bibr">90</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gold NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H1N1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Membrane matrix protein 2 (M2e)/CpG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranasal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-nanomaterials-10-01072" ref-type="bibr">91</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gold NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FMDV <sup>a</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Foot and mouth disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intradermal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B92-nanomaterials-10-01072" ref-type="bibr">92</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gold NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H1N1, H3N2, H5N1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M2e/CpG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranasal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B93-nanomaterials-10-01072" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitosan NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBV <sup>b</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBsAg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intraperitoneal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B94-nanomaterials-10-01072" ref-type="bibr">94</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carbon magnetic NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hen egg lysozyme</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B95-nanomaterials-10-01072" ref-type="bibr">95</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitosan NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NV <sup>c</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live virus vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Newcastle disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranasal or oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B96-nanomaterials-10-01072" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCL <sup>d</sup>/chitosan NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBsAg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranasal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B97-nanomaterials-10-01072" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b3;-PGA NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H1N1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemagglutinin (HA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranasal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B98-nanomaterials-10-01072" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Capsid protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Norwalk virus infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B88-nanomaterials-10-01072" ref-type="bibr">88</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nucleocapsid protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B89-nanomaterials-10-01072" ref-type="bibr">89</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H3N2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Structural proteins, e.g., HA, neuraminidase, NA, and matrix (M1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B99-nanomaterials-10-01072" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RV <sup>e</sup> 8-2/6/7-VLP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple proteins, e.g., cholera toxin (CT) and <italic>Escherichia coli</italic> heat-labile toxin (LT)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rotavirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rectal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-nanomaterials-10-01072" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polypeptide NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CoV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral protein (spike)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B101-nanomaterials-10-01072" ref-type="bibr">101</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alginate coated chitosan NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBsAg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranasal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B102-nanomaterials-10-01072" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLA and PLGA NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B surface antigen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pulmonary or intramuscular</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B103-nanomaterials-10-01072" ref-type="bibr">103</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLA and PLGA nano/micropraticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TT <sup>f</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetanus toxoid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetanus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-nanomaterials-10-01072" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BPI3V <sup>g</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BPI3V proteins</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bovine respiratory</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranasal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B105-nanomaterials-10-01072" ref-type="bibr">105</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polyanhydride</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F and G glycoproteins</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bovine respiratory syncytial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranasal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B106-nanomaterials-10-01072" ref-type="bibr">106</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPMA/NIPAM <sup>h</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F protein/TLR-7/8 agonist</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV, influenza, HIV-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular, intranasal, intravenous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B107-nanomaterials-10-01072" ref-type="bibr">107</xref>,<xref rid="B108-nanomaterials-10-01072" ref-type="bibr">108</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DLPC <sup>i</sup> liposomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H1N1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M2, HA, NP/MPL <sup>j</sup> and trehalose 6,6&#x02032; dimycolate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular, intratracheal, intranasal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B109-nanomaterials-10-01072" ref-type="bibr">109</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cationic nanomicelles based on PSA <sup>k</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PSA/mRNA encoding</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV/AIDS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B110-nanomaterials-10-01072" ref-type="bibr">110</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Foot-and-mouth disease virus; <sup>b</sup> hepatitis B virus; <sup>c</sup> Newcastle virus; <sup>d</sup> poly-&#x003b5;-caprolactone; <sup>e</sup> Rotavirus; <sup>f</sup> tetanus toxoid; <sup>g</sup> bovine parainfluenza 3 virus; <sup>h</sup> N-(2-hydroxypropyl)methacrylamide/N-isopropylacrylamide; <sup>i</sup> dilauroylphosphatidylcholine; <sup>j</sup> monophosphoryl lipid A; <sup>k</sup> polyethyleneimine-stearic acid.</p></fn></table-wrap-foot></table-wrap></floats-group></article>